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resumo 
 
 
A prevalência de isolados bacterianos, da família Enterobacteriaceae, resistentes a 
cefalosporinas de largo espectro, produtores de β-lactamases de largo espectro (ESBLs) 
e/ou AmpCs tem vindo a aumentar. Tem sido também reportada a coocorrência de genes 
que codificam para ESBLs e genes que conferem resistência a outras classes de 
antibióticos. Esta situação tem como consequências a limitação de opções terapêuticas e 
o insucesso da terapia, traduzindo-se em taxas de mortalidade e morbilidade mais 
elevadas.  
Este trabalho focou-se na caracterização molecular de 46 isolados clínicos resistentes a 
antibióticos, pertencentes à família Enterobacteriaceae. Os isolados foram previamente 
obtidos no Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga, E.P.E., e foram 
selecionados para análise com base na suspeita de produção de ESBLs e/ou AmpCs, de 
acordo com o sistema automático Vitek2®. Os isolados foram caraterizados em termos de 
diversidade genotípica, presença de genes de resistência e elementos genéticos móveis. 
Foram observados determinantes genéticos responsáveis pela resistência a β-lactâmicos  
(blaTEM, blaSHV, b laCTX-M e b laCMY), fluoroquinolonas (qnrA, qnrB e aac(6’)-ib-cr), 
sulfonamidas (sul1 e sul2) e aminoglicosídeos (aac(6’)-ib). O gene blaTEM foi o mais 
prevalente (97,8%), enquanto o gene blaSHV foi o menos prevalente (6,5%) entre os 
isolados. A variante blaCMY do gene blaAmpC foi a mais frequente em contexto adquirido 
(n=10 isolados). A variante b laCTX-M-15 foi observada na maioria (94,4%) dos isolados 
blaCTX-M+ e surge associada à sequência de inserção ISEcp1. Foram identificados genes 
codificantes para o fenótipo de resistência a aminoglicosídeos (aadA1, aadA2, aadA5 e 
aadB), trimetoprim (dfrA1, dfrA12, dfrA15 e dfrA17), cloranfenicol (catB3) e estreptotricina 
(sat2) nas regiões variáveis dos integrões de classes 1 e 2, presentes em 34 e 1 isolados, 
respetivamente. Além dos integrões, foram encontrados outros elementos genéticos 
móveis como sequências de inserção, nomeadamente, ISEcp1 e plasmídeos conjugativos 
pertencentes aos grupos IncF, IncK, IncB/O e IncI1. Foram realizados ensaios de 
conjugação para 8 isolados blaCTX-M-15+ e 7 isolados blaCMY+, originando 2 e 3 
transconjugantes, respetivamente. 
Com este trabalho foi possível concluir que a resistência às cefalosporinas de 3ª geração 
neste hospital está predominantemente associada a mecanismos de resistência adquirida. 
Os resultados referentes à tipagem molecular, recorrendo a BOX-, ERIC- e rep-PCR, 
sugerem que a disseminação de produtores de ESBLs e/ou AmpCs neste hospital será 
policlonal, dada a variabilidade intra-espécies observada. Não se identificaram clones 
prevalentes em diferentes serviços ou associados à comunidade . De facto, a 
disseminação dos determinantes de resistência parece estar relacionada com 
transferência de elementos genéticos móveis, nomeadamente dos replicões IncB/O, K, I1 
e Frep. A presença de integrões nestes isolados resulta com frequência em fenótipos de 
multirresistência. Serão necessários mais estudos para caracterizar os elementos 
genéticos móveis com maior detalhe. O estudo aqui apresentado representa uma 
contribuição importante para a definição de estratégias de controlo da disseminação de 
bactérias resistentes a cefalosporinas de largo espectro no Hospital Infante D. Pedro. 
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abstract 
 
The prevalence of Enterobacteriaceae isolates displaying resistance to broad-spectrum 
cephalosporins, harboring extended-spectrum β-lactamases (ESBLs) and/or AmpC 
enzymes is increasing. Moreover, the co-occurrence of ESBLs and genes conferring 
resistance to other antibiotic classes is frequently reported. This situation  leads to a 
limitation of therapeutic options and unsuccessful therapy and consequently to higher rates 
or mortality and morbidity.  
This work focused on the molecular characterization of 46 antibiotic resistant clinical 
isolates belonging to Enterobacteriaceae family. These isolates were previously obtained 
from Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga, E.P.E., and were 
selected for analysis based on the suspicion of ESBL and/or AmpC production provided by 
the Vitek2® Automatic System. The isolates were characterized in terms of genetic 
diversity, resistance genes and mobile genetic elements . Genetic determinants conferring 
resistance to β-lactams (blaTEM, blaSHV, b laCTX-M and b laCMY), fluoroquinolones (qnrA, qnrB 
and aac(6’)-ib -cr), sulfonamides (sul1 and sul2) and aminoglycosides (aac(6’)-ib) were 
observed. blaTEM was the most prevalent gene (97.8%) while blaSHV gene was the least 
prevalent (6.5%) among isolates. blaCMY variant of the blaAmpC genes was the most frequent 
in an acquired context (n=10 isolates). blaCTX-M-15 variant was found in the majority of the 
isolates that tested positive for the blaCTX-M gene (94.4%) and is frequently associated with 
the insertion sequence ISEcp1. Resistance genes coding resistance phenotype to 
aminoglycosides (aadA1, aadA2, aadA5 and aadB), trimetoprim (dfrA1, dfrA12, dfrA15 and 
dfrA17), chloramphenicol (catB3), and streptothricin (sat2) were also identified in the 
variable regions of class 1 and 2 integrons, found in 34 and 1 isolates, respectively. Aside 
from integrons, other mobile genetic elements like insertions sequences, ISEcp1 and 
conjugative plasmids belonging to groups IncF, IncK, IncB/O and IncI1, were also 
identified. Mating assays were performed for 8 blaCTX-M-15+ isolates and 7 blaCMY+ isolates, 
originating 2 e 3 transconjugants, respectively. 
It was possible to conclude that resistance to 3rd generation cephalosporins in this hospital 
is predominantly associated with acquired mechanisms. Molecular typing results, obtained 
by BOX-, ERIC- and rep-PCR, suggest a non-clonal dissemination of the ESBL and/or 
AmpC-producing isolates, based on the high intra-species diversity observed. Clones 
prevalent in the hospital or prevalent in the community were not identified. In fact, the 
dissemination of the resistance determinants seems to be related to the transference of 
mobile genetic elements , namely IncB/O, K, I1 and Frep replicons. Also, the presence of 
integrons often results in a multidrug phenotype. Further studies need to be conducted to 
identify these elements with more detail. This study represents an important contribution to 
the development of effective strategies aiming to reduce the dissemination of broad -
spectrum cephalosporins resistant bacteria in Hospital Infante D. Pedro. 
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I. INTRODUCTION 
 
1. Antibiotics 
An antibiotic can be defined as a substance that has the capacity to kill 
(bactericides) or selectively inhibit the growth of bacteria (bacteriostatic) by specific 
interactions with cell targets. These compounds can either have a synthetic or a natural 
origin and can be used to treat or to prevent bacterial infections (Davies & Davies, 2010).  
In 1928, Alexander Fleming accidently discovered penicillin, a natural compound 
with antimicrobial properties. While examining his culture-plates of Staphylococcus, 
Fleming noticed that around the colonies of the contaminating mold, Staphylococcus 
colonies did not grow. There were made subcultures of this mold, later identified as 
Penicillium notatum, with the aim to isolate the antimicrobial substance (Fleming, 1980). 
Penicillin, along with other antimicrobials discovered in the Antimicrobial Era, that is the 
large-scale production and introduction of antibiotics in clinical facilities, mark the future 
of antimicrobials discovery (Aminov, 2010). 
Penicillin had the capacity to kill or affect the growth of the majority of common 
pathogenic bacteria when discovered. A few years later, in 1945, after mass production 
and distribution, penicillin was used as treatment for infections of sick and wounded 
soldiers in the U.S. and Allies’ military forces. Thereafter, penicillin became a widely 
used antibiotic for infectious diseases that were previously untreatable (Aminov, 2016). 
After the discovery of penicillin, numerous antibiotics were discovered and 
developed. Today, there are several classes of antibiotics which differ in their targets but 
they all act on central processes/structures distinctive of bacterial cells. As a consequence, 
their negative effects in eukaryotic cells are minimized (Neu, 1992). 
The discovery of these compounds and their application in medical practice to 
treat and prevent diseases had a great health impact on human morbidity and mortality 
rates thus saving numerous lives. Besides their application in human medicine, antibiot ics 
can also be used in veterinary medicine and agricultural practices. 
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 1.1 Classes of antibiotics and their mechanism of action 
  
 As mentioned before, since the discovery of penicillin the number of antibiot ics 
available increased, which required a system to classify them. The most practical system 
is the one where antibiotics are classified based on their mechanism of action (Neu, 1992). 
These mechanisms include: inhibition of protein synthesis, inhibition of synthesis or 
metabolism of nucleic acids, inhibition of the synthesis or damage of the bacterial cell 
wall or modification of energy metabolism of the prokaryotic cell. 
 Table I.1 is a summary of the classification of the main classes of antibiot ics 
according to their mechanism of action. 
  
 
Table I.1. Classification of antibiotic classes according to their action mechanism. 
 
Mechanism of Action Antibiotic Class 
 
 
Inhibition of protein synthesis 
 
 
 
Aminoglycosides 
Phenicols 
Macolides-Lincosamides-Streptogramins B 
(MLS) 
Tetracyclines 
 
Interaction with the synthesis of nucleic acids 
(DNA and RNA) 
 
 
(Fluoro)quinolones 
 
 
Inhibition of the synthesis/damage of the 
bacterial cell wall 
 
β-lactams 
Glycopeptides 
 
Modification of the energy metabolism of the 
bacterial cell 
 
Sulfonamides 
Trimethoprim 
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   1.1.1. β-Lactams 
Due to their versatility, low toxicity, and broad spectrum of action as well as their 
high safety, efficacy, and availability, β-lactams play a major role in the treatment of 
bacterial infections (Bush, 2010; Bush & Jacoby, 2010).  
β-lactams act on the bacteria cell wall, by inhibiting its synthesis when they bind 
to penicillin-binding proteins (PBPs) thus preventing terminal transpeptidation in the 
prokaryotic cell wall. Consequently, since the bacteria cell wall is weaker, occurs 
cytolysis or death due to osmotic pressure (Van Hoek et al., 2011). 
Identification of 6-aminopenicillanic acid as the core of penicillin allowed a 
starting point for the development of derivatives. Thus, this class of antibiotics now 
includes several sub-groups, namely: penicillins and derivatives, cephalosporins, 
carbapenems, monobactams and β-lactamase inhibitors. Aside from β-lactamase 
inhibitors, all of these sub-classes contain a β-lactamic ring in their structure which is 
characteristic of this family of antibiotics (Van Hoek et al., 2011). 
 The sub-group of penicillins and derivatives is composed by natural and 
semisynthetic penicillins, such as derivatives that are active against Gram-negative 
bacteria like ampicillin and amoxicillin (Aminov, 2016). 
Cephalosporins can be grouped in 1st, 2nd, 3rd and 4th generation cephalosporins 
according to their spectrum of activity and time of introduction as therapeutic agents 
(Donowitz & Mandell, 1988). 3rd and 4th generation cephalosporins have a broader 
antibiotic activity spectrum compared to 1st and 2nd generations (early-cephalosporins). 
3rd generation cephalosporins have an improved Gram-negative and variable Gram-
positive activity and 4th generation cephalosporins have a good broad spectrum of activity 
against Gram-negatives as well as Gram-positives. Ceftazidime and cefotaxime are 
examples of 3rd generation cephalosporins and cefepime is an example of 4rd generation 
(Van Hoek et al., 2011). 
Carbapenems, like imipenem and meropenem, are considered as broad spectrum 
β-lactams due to their broad spectrum of activity (Van Hoek et al., 2011). 
Sub-group β-lactamase inhibitors have minor antimicrobial activity and are used 
in combination with other β-lactams to overcome resistant bacteria that express β-
lactamases. Tazobactam, sulbactam and clavulanic acid are clinical irreversible β-
lactamase inhibitors since they will cause the destruction of the enzymatic activity (Van 
Hoek et al., 2011). 
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1.1.2. Other classes of antibiotics 
 Aside from β-lactam antibiotics, there are other classes of antibiotics that can be 
used to treat Gram-negative infections, for example, aminoglycosides, chloramphenico l, 
(fluoro)quinolones, sulfonamides, trimethoprim and tetracyclines.  
 Aminoglycosides, like streptomycin (discovered in the early 1940s), neomycin 
and kanamycin, isolated from Streptomyces species and gentamicin, isolated from 
Micromonospora purpurea, have a broad spectrum activity (Schatz & Waksman, 1944). 
They inhibit protein synthesis and/or alter the integrity of the cell membranes and can act 
in combination with other antibiotics (Vakulenko & Mobashery, 2003). 
 As aminoglycosides, chloramphenicol (1947) and its synthetic derivatives act as 
inhibitors of protein synthesis. They bind to a peptidyltransferase of a subunit of the 70S 
ribosome and prevent peptide chain elongation (Schwarz et al., 2004). 
 Fluoroquinolones (1962) are the second generation of quinolones and the result 
of an addition of a fluoride atom to the structure of a quinolone molecule. Ciprofloxac in 
is an example of these molecules. This alteration improved their biological activity so 
further alterations were made, resulting in the third generation fluoroquinolones (e.g. 
levofloxacin) which have activity against both Gram-negative and Gram-positive bacteria 
(Van Hoek et al., 2011; Wolfson & Hooper, 1989). 
Sulfonamides are the oldest synthetic therapeutics (1932) and they act on the folic 
acid pathway. Due to its structural analogy to p-aminobenzoic acid, sulfonamides 
competitively inhibit the enzyme dihydropteroate synthase (DHPS), inactivating the 
thymine production which affects the cell growth. Nowadays, sulfamethoxazole is the 
most commonly used sulfonamide and is used in combination with trimethoprim. Like 
sulfonamides, trimethoprim is a class of completely synthetic drugs and they act on the 
metabolism of the cell as well, in this case, trimethoprim inhibits the enzyme 
dihydrofolate reductase (DHFR) that is part of the folic acid pathway like DHPS (Roberts, 
2002). 
Tetracyclines are second after penicillin in world consumption because of their 
broad spectrum of activity, relative safety and low cost. They inhibit the growth of the 
bacteria by interacting with the ribosomes then blocking the protein synthesis. One 
example of compounds included in this class is chlortetracycline (Roberts, 2002). 
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2. Antibiotic Resistance 
In 1940, before the introduction of penicillin in medical practices, two members 
of the penicillin discovery team observed that some Escherichia coli bacteria had the 
ability to destroy penicillin through the production of an enzyme, named penicillinase, 
thus becoming resistant to penicillin (Abraham & Chain, 1940).  However, the scenario 
was more or less optimist. It was assumed that the frequency of mutations that led to 
antibiotic resistance was negligible and the exchange of genetic material between bacteria 
was not expected (Davies & Davies, 2010).  
Alexander Fleming was one of the firsts to alert to this resistance to penicillin. In 
1945, in his Nobel Lecture, Fleming stated that penicillin would be easily available to 
anyone and this, associated with an inadequate treatment, either due to under-dosages or 
smaller treatment periods than the recommended ones, would result in resistant bacteria 
(Fleming, 1945). The scenario presented for penicillin and the emergence of resistance, 
is also seen in other antibiotics. Upon the introduction of an antibiotic, within a few years, 
resistance mechanisms emerge, compromising the efficiency of the antibiotic (Van Hoek 
et al., 2011). 
Besides self-medication and misprescription of antibiotics, there are numerous 
factors influencing the increasing emergence of antibiotic resistance and most of them are 
anthropogenic, namely: (i) the use of antibiotics as growth promotors in animals, (ii) the 
prophylactic use in humans, animals and aquaculture and (iii) agriculture usage as pest 
control. All of these activities release antibiotics into the environment providing a 
constant selection and pressure for resistant populations which result in environmenta l 
reservoirs of resistance (Davies & Davies, 2010).   
Mutation and selection, together with mechanisms of gene transfer among 
bacteria, provide a rapid adaptation of these bacteria to the introduction of an antibiot ic 
in their environment.      
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2.1 Intrinsic and acquired resistance  
 Antibiotic resistance can either be intrinsic or acquired. Intrinsic resistance refers 
to an innately resistance conferred by genes in the bacteria genomes that could lead to a 
resistance phenotype. In this case, bacteria are innately resistant to one (or more) classes 
of antibiotics (Davies & Davies, 2010).  
 Acquired resistance emerges when a bacteria that was initially susceptible to one 
antibacterial agent starts to display a resistance phenotype that allows its proliferation in 
the presence of that agent. This resistance can arise via new mutations or by acquisit ion 
of genetic information encoding resistance from other bacteria. The first event occurs 
spontaneously in the chromosome and can either cause resistance through several 
mechanisms or can just reduce the susceptibility of the bacteria to an antibiotic allowing 
its initial survival until the bacteria acquires other mutations or genes that confer antibiot ic 
resistance. The second event is termed horizontal gene transfer (HGT) and occurs through 
genetic exchange mechanisms. This event plays the major role in the evolution and 
transmission of resistance to antibiotics among bacteria (Magiorakos et al., 2012; 
Tenover, 2006). 
 
2.1.1 Mechanisms of horizontal gene transference   
 There are three main processes that promote horizontal HGT: transformation, 
transduction and conjugation. Transformation occurs when a competent bacteria is 
capable of uptake, integrate and express fragments of DNA present in the extracellular 
environment. In transduction, bacteriophages can transfer genes between bacteria. 
Bacterial DNA, along with phage DNA, is packaged into the phage head and then can be 
integrated and expressed in the recipient bacterial cell. Conjugation events require cell to 
cell contact since DNA transference from the donor cell to the recipient cell occurs via 
cell surface pili (Von Wintersdorff et al., 2016). 
 Transformation occurs without an intermediary platform. On the other hand, 
transduction and conjugation require a vehicle for gene transference. This first involves 
bacteriophages and the second requires exchange of genetic elements like plasmids, 
transposons, integrons and/or insertion sequences.  
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2.1.1.1 Plasmids  
Plasmids are circular or linear extra chromosomal elements that replicate 
autonomously in a host cell and can be found in almost all bacterial species. In their 
structure, plasmids contain genes essential for replication and may contain accessory 
genes that confer useful phenotypes to their host, like virulence or antibiotic resistance 
genes (Carattoli, 2009). Although plasmids can contribute for genetic diversity, they do 
not necessarily increase the host fitness because their presence carries a fitness burden for 
the host.  
The simplest of these structures contain an origin of replication and associated 
genes. Mobilizable plasmids, apart from genes associated with replication, also contain 
an origin of transfer (oriT) and conjugative plasmids contain an origin of replication 
(oriR), an oriT and genes encoding functions allowing them to transfer to another host 
(Van Hoek et al., 2011).  
Since some plasmid types cannot coexist in the same bacterial cell, the system of 
plasmid classification relies on incompatibility (Inc) groups. Plasmids that do not 
propagate on the same cell line belong to the same Inc group while plasmids that belong 
to different Inc groups can coexist on the same cell and can both be transferred to the 
daughter cells. This classification system also allows the evaluation of the transferability 
of plasmids carrying resistance determinants among bacteria. In Enterobacteriaceae the 
major plasmid families found are HI2, HI1, I1-ϒ, X, L/M, N, FIA, FIB, FIC, W, Y, P, 
A/C, T, K and B/O (Carattoli, 2009).   
  
 
2.1.1.2 Transposons, integrons and insertion sequences 
Integrons are genetic platforms that acquire gene cassettes in their environment 
by recombination, and convert them into functional genes by ensuring their correct 
expression, thus increasing genetic diversity in bacteria (Mazel, 2006). From the 
structural point of view, integrons are composed of three key elements: a gene encoding 
an integrase (intI), a recombination site (attI) and a promoter (Pc) that directs transcript ion 
of the captured genes. These elements allow the capture of exogenous genes, like 
antibiotic resistance genes (Mazel, 2006). Figure I.1 illustrates the structure of an integron 
and the mechanism of exogenous capture of gene cassettes.  
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There are three major integron classes which are frequently found in clinica l 
environments, classes I, II and III, which differ in the sequence of the integrase gene. 
Integrons are not considered mobile DNA elements for themselves since they do not 
include any genes encoding for mobility. However, they can be integrated into mobile 
elements, like plasmids or transposons, contributing to the dissemination of antibiot ic 
resistance determinants among bacteria (Boucher et al., 2007).   
 
Figure I.1 - Integration of gene cassettes into an integron. Retrieved from http://integrall.bio.ua.pt/?intro 
 
Insertion sequences (IS) are the simplest of mobile genetic elements. They 
consist in a segment of DNA with the ability of insert at multiple sites in a target DNA 
(Boucher et al., 2007). Insertion sequences, like ISEcp1, have been implicated in the 
mobilization of antibiotic resistance genes onto plasmids since they facilitate this 
transference (Jacoby, 2009). Among IS, there is one particular type called Insertion 
Sequences Common Region (ISCR) which are elements close related to the IS91 family 
and are transposed by a mechanisms called rolling-circle transposition. While most IS 
need two copies to flank the mobilized gene, ISCRs, can transpose adjacent DNA 
sequences mediated by a single copy of the element (Toleman et al., 2006a). 
The majority of these elements are closely associated with antibiotic resistance 
genes, including resistance to β-lactams, aminoglycosides, chloramphenico l, 
trimethoprim and quinolones, and are also found beyond the 3’ Conserved Region (3’ 
CS) of class 1 integrons. This suggests that ISCR elements may play a role in the rapid 
transmission of the bacteria multi-drug resistance (Toleman et al., 2006a).    
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Insertion sequences containing genes that are not involved in its translocation are 
called transposons. Transposons are mobile DNA elements which have the ability to 
relocate within the genome due to the presence of a transposase. In some cases, can also 
be transferred to a recipient cell, like plasmids, and then they are termed conjugative 
transposons. This type of transposons have characteristic features of plasmids but do not 
contain an oriR and for that reason need to be integrated into DNA in order to be 
maintained (Van Hoek et al., 2011). 
Given these dissemination mechanisms, is easy to acknowledge that bacterial cells 
have a large potential to adapt to environments with the presence of antibiotics. They do 
so by acquiring antibiotic resistance genes either from other bacteria or directly from the 
extracellular environment. The presence of antimicrobial agents in the bacteria 
environment, forces the development of new mechanisms of resistance and this, 
associated with the capacity of rapid adaptation to selective pressures that bacteria 
possess, makes the dissemination of resistance to antibiotics an emergent problem since 
bacteria will continue to adapt (Tenover, 2006).  
 
 
2.2 Bacterial resistance mechanisms 
 Bacteria may manifest resistance to antimicrobial agents through a variety of 
mechanisms, including: (i) modification of the target, (ii) permeability alterations in the 
bacterial cell wall thus restricting the access of the antibiotic to its target, (iii) efflux of 
the antimicrobial agent from the bacteria, (iv) enzymatic modifications or degradation of 
the antibiotic, (v) overproduction of the target enzyme and (vi) alternative pathways to 
overcome the inhibition of the pathways inhibited by the antimicrobial agent (Van Hoek 
et al., 2011). Bacterial biofilms can also be considered a resistance mechanism to 
antimicrobial agents. Moreover, in these structures, HGT events and mutation frequency 
are significantly increased thus contributing to multidrug resistance phenotypes (Driffie ld 
et al., 2008; Molin & Tolker-Nielsen, 2003).   
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 2.2.1. β-lactams 
 There are several mechanisms that confer resistance to β-lactams. The most 
common and important among them is the production of enzymes named β-lactamases. 
Aside from that mechanism, when bacteria have altered penicillin-binding proteins 
(PBPs), β-lactams cannot bind to the PBPs, and as consequence, the antibiotic does not 
disrupt the cell wall with the same efficiency, leading to reduced sensibility of the bacteria 
to β-lactams (Dallenne et al, 2010; Van Hoek et al., 2011). 
 
2.2.1.1 β-lactamases 
β-lactamases are enzymes that have the capacity to hydrolyze the β-lactamic ring 
characteristic of this class of antibiotics. Consequently, the antibiotic loses the ability to 
kill the bacteria (Bush, 2010). 
These enzymes are encoded by bla genes and, due to their continuous mutations, 
there is, currently, a wide variety of β-lactamases, which led to classification systems. 
One system divides them according to amino acid sequences – molecular classes, where 
Ambler classes A, C and D comprise β-lactamases with serine at their active site and β-
lactamases that belong to Ambler class B are metallo-enzymes, requiring zinc as a metal 
cofactor (Ambler, 1980). Apart from molecular classes, functional groups divide β-
lactamases according to their inactivating properties, based on the hydrolysis and 
inhibition profiles of the enzymes. Serine β-lactamases belong to groups 1, 2 and 4 while 
members of group 3 are metallo-β-lactamases (Bush et al., 1995). 
 
  2.2.1.1.1 AmpC and extended-spectrum β-lactamases (ESBLs) 
AmpC β-lactamases, also known as cephalosporinases, belong to molecular class 
C and functional group 1. They confer resistance to penicillins, cephalosporins, 
oxyimino-cephalosporins, cephamycins and monobactams, and generally, are not 
inhibited by clavulanic acid, tazobactam or sulbactam (Jacoby, 2009). 
The production of AmpC β-lactamases can be chromosomally or plasmid 
mediated. AmpC are inducible enzymes found in chromosomes of most 
Enterobacteriaceae (Bush, 2010). They can be expressed at low and high levels, the latter 
due to mutations in the repressor gene ampD or in the regulator AmpR. High levels of 
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AmpC production confer resistance to broad-spectrum cephalosporins includ ing 
cefotaxime, ceftazidime, and ceftriaxone. This can be problematic since a bacteria isolate 
that was initially susceptible to these β-lactam antibiotics may become resistant during 
therapy (Jacoby, 2009).  
Plasmid-mediated AmpC β-lactamases have arisen through HGT of chromosomal 
AmpCs by transmissible plasmids among different species. For that reason AmpC β-
lactamases have been found on bacterial species that previously lacked the chromosomal 
blaAmpC gene or expressed AmpC at low levels (Jacoby, 2009).  
There are several types of plasmid mediated AmpC β-lactamases which are 
irregularly named, like: CMY, FOX, MOX and LAT, named according to the resistance 
produced to cephamycins, cefoxitin, moxalactam and latamoxef, respectively; ACT 
(AmpC type) and ACC (Ambler class C), named according with the type of  β-lactamase 
and according with the site of discovery, such as Miriam Hospital Providence, R.I. (MIR-
1) or Dhahran Hospital in Arabian Saudi (DHA), or the name of the patient from whom 
the microorganism was isolated such as Bilal (BIL-1) (Beceiro & Bou, 2004; Philippon 
et al., 2002). Figure I.2 represents a phylogenetic tree obtained in this work with the amino 
acid sequences of the representative variants of the AmpC cephalosporinases types 
described so far in order to represent the known diversity of these enzymes.  
 
Regarding the phylogeny of AmpC β-lactamases, it is worth to emphasize that 
CMY sequences grouped in two clusters that share the origin of the enzymes. The CMY-
1 group, represented by the varieties CMY-1, -8, -9, -10 and -11, is related to 
chromosome-encoded AmpC β-lactamases in Aeromonas spp., while the CMY-2 group 
(represented only by a part of the currently known varieties) is related to AmpC enzymes 
of Citrobacter freundii. CMY-2 is the most frequent plasmid-mediated AmpC β-
lactamase worldwide (Jacoby, 2009) and is also the most recent common ancestor of all 
plasmid-borne AmpC of C. freundii (Barlow & Hall, 2002). LAT enzymes have a similar 
origin, comparing to CMY-2. Of the four original LAT enzymes, it was discovered, by 
sequence analysis, that LAT-2 was identical to CMY-2, LAT-3 was identical to CMY-6 
and LAT-4 was actually identical to LAT-1, which is the only LAT enzyme remaining 
unique (Barlow & Hall, 2002; Jacoby, 2009). 
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Also, BIL-1 is not represented since its sequence is identical to CMY-2. For the 
same reason, LAT-2 is not represented either (Barlow & Hall, 2002). That said, CMY-2 
could be listed as CMY-2-BIL-1-LAT-2, the common ancestor of plasmid 
cephalosporinases.   
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Figure I.2 - Molecular Phylogenetic analysis by Maximum Likelihood method using MEGA7. The percentage 
of trees in which the associated taxa clustered together is shown next to the branches. Initial tree(s) for the 
heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of 
pairwise distances estimated using a JTT model, and then selecting the topology with superior log likelihood 
value. The designation used in the tree includes the amino acid sequence accession number for each enzyme. 
The tree includes only sequences representatives of each family among all the variants described so far.    
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ESBLs belong to functional group 2be and molecular class A. These enzymes are 
capable of hydrolyzing early- and expanded-spectrum cephalosporins and monobactams, 
but not cephamycins and carbapenems. Additionally, ESBLs are inhibited by β-lactamase 
inhibitors (clavulanic acid, sulbactam and tazobactam) (Bush, 2010). This property and 
the susceptibility to cephamycines distinguishes ESBLs from AmpCs.   
TEM, SHV and CTX-M are the three main families of ESBLs described. The 
genes encoding these ESBLs are generally found in plasmids
 
that confer resistance to 
multiple antibiotic classes and that are easily transferable among bacteria (Bush, 2010). 
Initially, all ESBLs were identified as variants of the TEM-1 and SHV-1 β-
lactamases, since they arise via point mutations from these two narrow-spectrum β-
lactamases. TEM-1 and SHV-1 penicillinases (group 2b/class A) include the SHV-1 
enzyme found in Klebsiella pneumoniae and the TEM-1 and -2 β-lactamases found in 
Neisseria gonorroheae and Haemophilus influenza, encoded by blaSHV, blaTEM-1 and 
blaTEM-2, respectively (Bush, 2010). These enzymes hydrolyze penicillins and early 
cephalosporins, such as cephaloridine and cephalothin are inhibited by clavulanic acid, 
sulbactam and tazobactam (Bush & Jacoby, 2010). This group of enzymes were the most 
common plasmid β-lactamases identified in the 1970s and early 1980 (Bush & Jacoby, 
2010) and were prevalent among Enterobacteriaceae before the introduction of the 
broad-spectrum cephalosporins (Bush, 2010). It is thought that the use of 3rd generation 
cephalosporins acted as a selective pressure thus being responsible for the arise of these 
variants displaying resistance to 3rd generation cephalosporins (Paterson & Bonomo, 
2005). Despite these variants of TEM-1 and SHV-1 penicillinases, in the late 1980s CTX-
M family – encoded by blaCTX-M genes, arose and within a decade, became the 
predominant ESBL family, outnumbering most of the TEM- and SHV-derived ESBLs 
(Seiffert et al., 2013). 
CTX-M family preferentially hydrolyzes cefotaxime and some CTX-M-type 
ESBL actually have hydrolyzing activity against ceftazidime thus conferring resistance 
(Paterson & Bonomo, 2005). In addition to the unique feature of the rapid hydrolysis of 
cefotaxime, CTX-M enzymes, are also distinctive in the fact that they are better inhib ited 
by tazobactam than by sulbactam and clavulanic acid (Shaikh et al., 2015). 
It appears that CTX-M β-lactamases have a different origin than TEM and SHV 
ESBLs. These latter ESBLs are originated by amino acid substitutions of their parent 
enzymes but CTX-M family is thought to be originated by HGT mechanisms since they 
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are closely related to chromosomal β-lactamases of Kluyvera spp.. As an example, CTX-
M-8 shares 99% amino acid identity with chromosomal β-lactamase KLUG-1 of 
Kluyvera spp. and compared to TEM and SHV β-lactamases, CTX-M-type, only have 
40% or less identity (Paterson & Bonomo, 2005).  
The number of CTX-M has been rapidly expanding and so is their geographic 
dissemination. Among all variants, CTX-M-15 is the most frequent and one of the most 
spread CTX-M β-lactamases in the community and in clinical settings (Cantón & Coque, 
2006).  
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2.2.2 Other classes of antibiotics 
  2.2.2.1 Aminoglycosides 
 Among all of the resistance mechanisms against aminoglycosides, the main one 
is the inactivation of the antibiotic by aminoglycoside-modifying enzymes. These 
enzymes are classified, according to the type of modification, in the following major 
classes: ACC (acetyltranferases), ANT (nucleotidyltransferases/ adenyltransferases) and 
APH (phosphotransferases) (Vakulenko & Mobashery, 2003). 
 
  2.2.2.2 Chloramphenicol 
 Resistance to chloramphenicol emerges mostly by enzymatic inactivation by 
acetylation through chloramphenicol acetyltransferases (CATs) which are coded by catA 
and catB genes. Besides this mechanism, inactivation by phosphotransferases, mutations 
of the target site, permeability barriers and efflux systems – coded by floR and cmlA 
genes, were also reported (Schwarz et al, 2004). 
 
  2.2.2.3 Fluoroquinolones 
 Resistance to fluoroquinolones can be chromosome-encoded and plasmid-
mediated. Chromosomal resistance results, mainly, from mutations in the target enzymes 
of fluoroquinolones, DNA gyrase and DNA topoisomerase IV. These mutations occur at 
specific “quinolone resistance determining regions” in the genes gyrA, gyrB, parC and 
parE, that are located in the DNA-binding surface, thus reducing the affinity of the 
quinolone biding. Apart from this system, chromosome-encoded resistance can also result 
by decreasing the intracellular concentration of the antibiotic either by overexpression of 
efflux pumps or by diminished expression of outer membrane porins (Jacoby, 2005).  
 Plasmid-mediated resistance  can emerge from three different genes families, qnr, 
aac(6’)-Ib-cr and qepA. The first one encodes a protein, called Qnr protein, capable of 
protecting DNA gyrase from quinolones. Currently, there are five families of qnr genes: 
qnrA, qnrB, qnrC, qnrD, qnrS and qnrVC. The second gene, aac(6’)-Ib-cr, is a variant of 
aac(6’)-Ib, which confers resistance to aminoglycosides, and has the ability of reducing 
ciprofloxacin activity. The last mechanism, coded by qepA genes, is an efflux pump 
(Robicsek et al, 2006; Strahilevitz et al, 2009).  
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2.2.2.4 Sulfonamides 
 Sulfonamides are synthetic antibiotics so it was not expected that enzymes capable 
of degrade or modify sulfonamides would emerge. Nevertheless, low level chromosomal 
resistance occurs by mutations in the folP gene that encodes DHPS (Sköld, 2001). 
Plasmid-mediated resistance can also occur by sul1, sul2 and sul3 genes, coding variants 
of DHPS (Perreten & Boerlin, 2003; Radstrom & Swedberg, 1988; Swedberg & Skold, 
1983). 
 
2.2.2.5 Trimethoprim 
 Trimethoprim as well sulfonamides, is a synthetic antibiotic. Low level resistance 
can occur via mutations of the folA gene which encodes DHFR. High level resistance 
occurs through acquisition of DHFRs variants, coded by dfrA and dfrB genes (Sköld, 
2001). 
 
2.2.2.6 Tetracyclines 
 There are three main mechanisms conferring resistance to tetracyclines: efflux-
pumps, ribosomal protection proteins (PBPs) and enzymatic inactivation – this latter 
mechanism has only been identified in Gram-negative bacteria so far. These mechanisms 
are coded by tet (tetracycline resistance) and otr (oxytetracycline resistance) genes 
(Chopra & Roberts, 2001). 
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3. Antibiotic resistance in clinical environment 
Clinical infections can be hospital- or community-acquired and can be caused by 
a variety of organisms, including viral, fungal and bacterial pathogens. 
Hospital-acquired infections, also known as nosocomial infections, are acquired 
in hospitals or healthcare service units and are unrelated to the original illness that led the 
patient to the healthcare facility. These infections appear, at least, 2 days after the patient 
admission or within 30 days after the patient discharge (Horan et al., 2008). By 
opposition, community-acquired infections are contracted outside the healthcare setting 
and are present in the moment of admission.  
Nosocomial infections represent a real concern since they interfere with the 
appropriate treatment of the patient and according to Direção-Geral da Saúde (Direção-
Geral da Saúde, 2014), about 1/3 of these bacterial infections are inevitable. These 
infections can be transferred by direct or indirect contact either among patients, healthcare 
workers, visitors, contaminated objects or environmental sources (e.g. hospital food). 
There are patient and environmental related risk factors for the development of these 
infections, namely: age more than 70 years, major trauma, acute renal failure, prior use 
of antibiotics, mechanical ventilation, drugs that affect the immune system (e.g. 
chemotherapy), indwelling (urethral or suprapubic) catheters and prolonged hospital stay 
(more than 3 days) (Siegel et al, 2007).  
Additionally, nursing homes may serve as a portal for the entry of these organisms 
into hospital settings. Antibiotic use is high in this type of facilities and the residents 
require frequent contact with health care providers. These arguments, associated with the 
fact that hand washing rates of nursing home personnel is low, makes nursing homes a 
focus of infectious organisms (Paterson & Bonomo, 2005). 
Hospital- and community-acquired infections can be monoclonal or polyclona l. 
Monoclonal infections are caused by organisms clonally related and are the most common 
type of epidemiology in hospital onset. This outbreak implies a transmission among 
patients, for example, through carriage on the hands of health care personnel, thus 
requiring the introduction of a strategy that controls this transmission. Polyclona l 
infections are more prevalent in the community but can also occur in hospital settings. 
This type of infection is probably due to selective pressure that is imposed by antibiot ic 
use (Paterson & Bonomo, 2005).   
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Antibiotic resistant pathogens are increasingly associated with nosocomia l 
infections. Moreover, longer hospital stay promotes the selection of resistant 
microorganisms. As a consequence, the growing number of resistant pathogens places a 
burden on healthcare systems by augmenting the mortality and morbidity rates and the 
diagnostic uncertainties, leading to an increase in treatment costs (Khan & Khan, 2016). 
Recently, the term “ESKAPE pathogens” has been used to describe a group of 
nosocomial pathogens that cause the majority of hospital infections and that have the 
ability of “escape” the effective therapy. This group encompasses both Gram negative 
and Gram positive species, namely: Enterococcus faecium, Straphylococcus aureus, 
Klebsiella pneumonia, Acinetobacter baumanii, Pseudomonas aeruginosa and 
Enterobacter spp. (Rice, 2008). Some authors, besides Louis B. Rice, consider that “K” 
encompasses both Klebsiella and Escherichia coli ESBL-producing species (Boucher et 
al., 2009; Peterson, 2009) while others suggested an alteration to the last “E” to 
“Enterobacteriaceae family” since isolates of E. coli, K. pneumonia, Enterobacter 
species and other members of this family are a threat that needs more attention (Khan & 
Khan, 2016).    
 
3.1. Antibiotic resistance in clinical isolates of Enterobacteriaceae 
The Enterobacteriaceae family, comprises several genera of Gram-negative 
bacteria including human pathogens, such as, Citrobacter, Enterobacter, Escherichia, 
Klebsiella, Morganella, Providencia, Salmonella, Serratia and Proteus. These 
microorganisms are considered as opportunistic pathogens as they normally cause 
infection in patients whose defenses are compromised (Brenner & Farmer, 2015).   
Enterobacteriaceae bacteria often harbor virulence factors and are responsible for 
a wide variety of hospital- and community-acquired infections, namely, urinary-tract 
infections (UTI), bloodstream infections, healthcare-associated pneumonias and several 
intra-abdominal infections. In particular, E. coli is a frequent cause of UTIs and surgical 
site infections, Klebsiella spp. and Enterobacter spp. cause pneumonias and, along with 
other members of this family, have been associated in bloodstream and intra-abdomina l 
infections, like cholangitis and peritonitis (Paterson, 2006). Although UTIs are the most 
common infections, either community- or hospital acquired – being the latter highly 
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associated with catheterization, lower respiratory tract and bloodstream infections are the 
most lethal (Horan et al., 2008).  
The primary choice for the treatment of serious infections caused by 
Enterobacteriaceae bacteria are 3rd generation cephalosporins. However, the production 
of ESBL and AmpC β-lactamases by these organisms leads to resistance against these 
antibiotics and complicates therapy, remaining an important reason for its failure (Peleg 
& Hooper, 2010). Organisms like Enterobacter spp. and Morganella morganii have 
intrinsic resistance to 3rd generation cephalosporins due to the overproduction of AmpC 
β-lactamases. The typical scenario when these antibiotics are administered is 
characterized by initial response followed by recurrence of the infection since the use of 
3rd generation cephalosporins results in selection of AmpC-overproducing mutants 
(Paterson, 2006). 
K. pneumoniae and E. coli are considered the major ESBL-producing organisms 
isolated worldwide. In Portugal, K. pneumoniae resistance to 3rd generations 
cephalosporins has been increasing (Figure I.3) and places this country in the second 
group with higher resistance rates in Europe (Direção-Geral da Saúde, 2016).  This 
scenario is also valid for E. coli isolates (Figure I.4), although the resistance rates are 
lower for these isolates than for K. pneumoniae isolates.   
 
 
Figure I.3 - K. pneumoniae resistance to 3rd generation cephalosporins in invasive isolates, in Portugal (2007-2014) 
(Direção-Geral da Saúde, 2016) 
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Figure I.4 – Resistance rates to 3rd generation cephalosporins in E. coli isolates found in Portugal (2007-2015). 
Adapted from: ResistanceMap, available at https://resistancemap.cddep.org/AntibioticResistance.php 
 
Aside from K. pneumoniae and E. coli, ESBL have also been identified in other 
members of the Enterobacteriaceae family. Regularly, these ESBL-producing organisms 
are multiresistant. This is due to the presence of ESBL encoding genes and genes coding 
for resistance to other antibiotic classes on the same plasmid. Typically, ESBL encoding 
genes are associated to genes that encode resistance to aminoglycosides, sulfonamides 
and fluoroquinolones (Paterson, 2006; Pitout & Laupland, 2008; Tacão et al, 2014).  
This multiresistance has serious consequences for the selection of adequate 
empirical therapy. Empirical therapy is the initial therapy when the infection was already 
diagnosed but the results of bacterial cultures identification and antimicrob ia l 
susceptibility tests are yet unknown. The presence of a multiresistant phenotype limits 
the therapeutic choices for infections caused by ESBL-producing bacteria from 
Enterobacteriaceae family and it is known that delays in the administration of appropriate 
antibiotic therapy are associated with elevated mortality rates (Pitout & Laupland, 2008).   
There are many concerns about the adequate therapy when multiresistant 
Enterobacteriaceae organisms cause infections because of the relative ease by which 
bacteria can develop antibiotic resistance mechanisms. As a result, some of the treatment 
options rely on carbapenems, including meropenem, imipenem, ertapenem and 
doripenem, as the first choice for serious infections caused by ESBL-producing bacteria 
(Peleg & Hooper, 2010). The potential selection of carbapenem-resistant variants 
sometimes leads to the choice of older and previously discarded antimicrobials such as 
colistin, which are associated with high toxicity, instead of carbapenems (Boucher et al., 
2009). These multiresistant Enterobacteriaceae bacteria pose such a serious threat to 
public health that World Health Organization (WHO) considers them as a “critical group” 
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for which research and development of antibiotics are needed (Tacconelli & Magrini, 
2017). 
The misuse and overuse of antibiotics along with the genetic plasticity of bacteria 
contributed to an increase in antibiotic resistance while the process of discovery and 
development of new antibiotics has suffered a reduction. This reduction is due to a 
number of factors, among them are the challenge of screening for new compounds, the 
time required to approve an antibiotic and the concern about new resistance emergency 
(Peleg & Hooper, 2010). Taken together, the rapid bacteria adaptation, the absence of 
new drugs and relative ease by which bacterial infections can be acquired generate a 
worrying public health concern regarding antibiotic resistance in bacteria.  
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4. Aims of this work 
The Enterobacteriaceae family includes a wide diversity of relevant pathogens 
namely, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter 
freundii and Morganella morganii. The increasing antibiotic resistance among these 
bacteria is a global concern, particularly in clinical settings. 3rd generation cephalosporins 
are a group of antibiotics widely used to treat infections caused by Gram-negative bacteria 
and are considered critically relevant in human medicine. 
A total of 46 isolates were obtained from different human biological samples from 
several wards in the Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga, 
E.P.E., Portugal, between January and December of 2014. These isolates were obtained 
in the scope of a previous work and were selected for analysis based on the suspicion of 
β-lactamase production provided by the Vitek2® Automatic System. Vitek2® was also 
used to determine the Minimum Inhibitory Concentration (MICs) to a range of antibiot ics 
for each isolate and to identify the isolate pathogen. 
The main goal of this work is to characterize the genetic basis of the resistance 
phenotypes as well as the dissemination potential of the genes present in these isolates, 
in this particular clinical setting, in order to contribute to the development of effective 
strategies to reduce resistance prevalence. 
 
Specific goals are: 
- To establish the genetic relatedness between isolates; 
- To detect and characterize antibiotic resistance (AR) genes; 
- To determine the genetic context of the identified genes; 
- To detect and characterize mobile genetic elements such as integrons and 
plasmids.  
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II. MATERIAL AND METHODS 
1. Clinical isolates 
The sampling process, bacteria isolation and identification were performed in the 
scope of a MSc thesis (Roxo, 2015). All clinical isolates characterized in this work were 
obtained in Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga, E.P.E., from 
January to December of 2014. 
The 46 isolates selected for this work were obtained from human biologica l 
samples from different wards (Table II.1) and were selected based on the suspicion of 
AmpC production given by Vitek2® Automated System. This was confirmed by a 
phenotypic test with cefoxitin discs. The co-production of an AmpC and an ESBL was 
also analyzed. Strains identified by Vitek2® as ESBL producers were confirmed using 
phenotypic test E-test with a cephalosporin and cephalosporin associated with clavulanic 
acid. 
Vitek2® automated system was also used to determine the MICs to a range of 
antibiotics for each isolate and to identify the isolate. The results obtained from Vitek2® 
concerning bacteria identification and resistance phenotype are presented in Table II.1. 
Results regarding antibiotic susceptibility testing are presented in supplemental material 
as Table S.1. 
Bacterial cells selected for this work (n=46) were cryopreserved at in glycerol at 
-80ºC. 
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Table II.1. Origin of the isolates used in this work: provenance of the patient and type of sample from 
which the isolate was obtained. Bacteria identification and resistance phenotype given by Vitek2® 
Automated System.   
Isolate Species Resistance Phenotype  
Provenance  
Sample  
Inpatients
 
Outpatients 
ER1 Escherichia coli AMC, AMP (a)  X Urine 
ER2 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  X  Urine (Foley catheter) 
ER3 Escherichia coli AMC, AMP, TZP, CAZ, CTX, CIP, LVX, SXT   X Urine 
ER4 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT   X Urine 
ER5 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  X  Urine 
ER6 Escherichia coli AMC, AMP, CIP, LVX, SXT   X Urine 
ER7 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT   X Urine 
ER8 Escherichia coli AMC, AMP, CAZ, CTX, LVX, SXT  X  Urine 
ER9 Enterobacter cloacae AMC, AMP  X Urine (bladder puncture) 
ER10 Enterobacter aerogenes AMC, AMP X  Urine 
ER11 Escherichia coli AMC, AMP, CAZ, CTX X  Pus 
ER12 Serratia marcescens Unknown X  Sputum 
ER13 Citrobacter freundii AMC, AMP,CAZ, CTX, CIP, LVX, SXT   X Urine 
ER14 Morganella morganii AMC, AMP, CIP, LVX  X Pus 
ER15 Escherichia coli AMC, AMP, CAZ, CTX X  Pus 
ER16 Enterobacter aerogenes AMC, AMP, CAZ, CTX X  Urine 
ER17 Enterobacter cloacae AMC, AMP X  Urine (Foley catheter) 
ER18 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  X  Pus 
ER19 Escherichia coli AMC, AMP, CIP, LVX, SXT  Unknown Urine 
ER20 Morganella morganii Unknown X  Sputum 
ER21 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  X  Urine (Foley catheter) 
ER22 Morganella morganii Unknown X  Sputum 
ER23 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  X  Catheter tip 
ER24 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT   X Urine 
ER25 Enterobacter aerogenes Unknown X  Sputum 
ER26 Escherichia coli AMC, AMP, CAZ, CTX X  Pus 
ER27 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT   X Urine 
ER28 Citrobacter freundii AMC, AMP, TZP,CAZ, CTX, CIP, LVX, SXT   X Urine 
ER29 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX X  Pus 
ER30 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  X  Urine (Foley catheter) 
ER31 Escherichia coli AMC, AMP, CAZ, CTX  X Urine 
ER32 Morganella morganii AMC, AMP, TZP, CAZ, CTX, CIP, LVX, SXT  X  Pus 
ER33 Escherichia coli AMC, AMP, TZP, CAZ, CTX  X Urine 
ER34 Morganella morganii AMC, AMP, TZP, CAZ, CTX, CIP, LVX, SXT   X Urine 
ER35 Escherichia coli AMC, AMP, CAZ, CTX X  Urine 
ER36 Escherichia coli AMC, AMP, CAZ, CTX, LVX X  Urine 
ER37 Enterobacter cloacae AMC, AMP, CAZ, CTX  X Urine 
ER38 Morganella morganii AMC, AMP, CAZ, CTX, CIP, LVX  X Urine (Foley catheter) 
ER39 Escherichia coli AMC, AMP, TZP, CAZ, CTX, CIP, LVX, SXT  X  Urine 
ER40 Escherichia coli AMC, AMP, TZP, CIP, LVX  X Urine (Foley catheter) 
ER41 Escherichia coli AMC, AMP, TZP, CIP, LVX  X Urine 
ER42 Enterobacter aerogenes AMC, AMP, TZP,CAZ, CTX X  Pus 
ER43 Escherichia coli AMC, AMP, TZP, CAZ, CTX X  Pus 
ER44 Enterobacter aerogenes AMC, AMP, TZP,CAZ, CTX X  Pus 
ER45 Enterobacter aerogenes AMC, AMP, TZP, CAZ, CTX X  Pus 
ER46 Providencia stuartii AMC, AMP, CAZ, CTX, CIP, LVX, SXT   X Urine 
aAntibiotic abbreviations: AMC, amoxicillin/clavulanic acid; AMP, ampicillin; TZP, piperacillin/tazobactam; CAZ, ceftazidime; 
CTX, cefotaxime; CIP, ciprofloxacin; LVX, levofloxacin; SXT, trimethoprim/sulfamethoxazole. 
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2. Genomic DNA extraction 
Genomic DNA was extracted from bacterial cells using Silica Bead DNA Gel 
Extraction Kit #K0513 (ThermoFisher Scientific, USA). The protocol used is described 
below.  
The success of the extraction experiment was confirmed by electrophoresis. A 
volume of 4µL of DNA was loaded on a 0.8% (w/v) Seakem® LE Agarose (Lonza, USA) 
gel 1x TAE (5Prime, Deutschland), in a ratio of 3:1 to 6x Loading Dye (MBI Fermentas, 
Lithuania).  
  
Preparation of genomic DNA from bacterial cells 
A. Cell-Lysis 
 Lysis protocol:  
1. Prepare pellets from fresh cells in Eppendorf tubes, keep frozen if necessary ; 
2. Resuspend (thawed) cell pellet in 100 µL of Buffer B1; 
3. Prepare mastermix of B1 with enzymes: per 1 mL add 2 µL of RNase A, 20 µL of 
Lysozym and 45 µL of Protease; 
4. Add 100 µL mastermix to each cell suspension; 
5. Vortex vigorously, incubate for at least 30 minutes at 37ºC;  
6. Add 70 µL of Buffer B2; 
7. Vortex vigorously, incubate for at least 30 minutes at 55ºC. 
At this point, the lysates can be used directly for DNA preparation or can be stored 
frozen. 
 DNA Preparation protocol: 
8. Add 500 µL  of Binding Solution to the 270 µL of lysate, vortex; 
9. Resuspend the Silica Suspension by vortexing for 1 minutes and add 5 µL; 
10. Incubate 5 minutes at 55ºC, invert from time to time; 
11. Centrifuge 5 seconds, remove supernatant; 
12. Suspend the pellet in 500 µL ice cold Wash Buffer; 
13. Centrifuge 5 seconds, remove supernatant; 
14. Repeat steps 11 and 12; 
15. Centrifuge the pellet again and remove all traces of the supernatant; 
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16. Air-dry the pellet at room temperature (~10 minutes); 
17. Resuspend the pellet in 50 µL of TE; 
18. Incubate 5 min at 55ºC; 
19. Centrifuge 2 minutes; 
20. Remove the supernatant = genomic DNA. 
Repeat the last centrifugation in case of transferring any silica particles to the DNA 
extract because this may inhibit subsequent enzymatic reactions, like restriction analysis 
or PCR. 
 
3. Polymerase Chain Reaction (PCR) amplification 
PCR was performed with extracted DNA or cell suspension from all 46 clinica l 
isolates. PCR reactions were performed in a volume of 25 µL in MyCycler Thermal 
Cycler (BioRad, USA) and all primers used were ordered from StabVida, Portugal or 
from Sigma, USA. Table II.2 represents the general reaction mixture, used for most of 
the amplification experiments. In each experiment negative and positive controls were 
used. The first one consisted in a substitution of the template DNA by the same volume 
of dH2O, in the reaction mixture, and the latter contained a DNA or cell suspension 
positive for the searched gene.  
 
 
Table II.2. General PCR reaction mixture.  
Sample reaction mixture  Volume (µL) 
NZYtech 2x Green Master Mix (2,5mM MgCl2; 
200µM dNTPs; 0.2U/µL DNA Polymerase) 
6.25 
Primer Forward (10 µM) 0.75 
Primer Reverse (10 µM) 0.75 
DNA (50-100ng/µL)/Cell suspension (0.5 
McFarland) 
1.00 
dH2O 16.75 
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Table II.3. PCR programs used for DNA amplification.  
 
PCR Programs 
Temperature 
(ºC) 
A  B  C  D  E  F G  Number 
of cycles 
94 5’ 5’ 10’ 5’ 5’ 5’ 5’ (x1) 
94 30’’ 30’’ 40’’ 30’’ 30’’ 30’’ 1’ 
(x 30) X 30’’ 30’’ 40’’ 30’’ 30’’ 30’’ 30’’ 
72 30’’ 1’ 1’ 90’’ 3’ 2’ 1’ 
72 7’ 7’ 7’ 5’ 10’ 10’ 5’ (x1) 
 
X - Annealing temperature for each primer set; A to G – different PCR programs used in this study. 
 
a. Molecular typing of resistant isolates 
Molecular typing analysis was performed to evaluate the diversity among the 
isolates. Three different PCR typing methods were used: BOX element polymerase chain 
reaction (BOX-PCR), Enterobacterial repetitive intergenic consensus (ERIC)-PCR and 
Repetitive element sequence-based PCR (REP-PCR). The combination of these thee PCR 
methods is known as rep-PCR. All primers used in this assay are presented in Table II.4. 
The PCR program used was Program H and it is presented in Table II.5. Annealing 
temperatures were 53ºC for BOX-PCR, 52ºC for ERIC-PCR and 40ºC for REP-PCR. The 
reaction mixture used for ERIC- and REP-PCR is the one described in Table II.2. For 
BOX-PCR, since it requires only one primer, a volume of 2µL of this primer is added to 
6.25µL of NZYtech 2x Green Master Mix and a volume of 16.25µL of dH2O is added to 
make a final volume of 25µL.  
PCR products were loaded in agarose gels for electrophoresis and the resulting 
band patterns were normalized and analyzed with software GelCompar II 6.1 (Applied 
Maths). Similarity matrices were calculated using the Dice coefficient and cluster analysis 
of similarity matrices was performed using the unweighted-pair group method using 
arithmetic average (UPGMA). 
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Table II.4. Primers used for molecular typing assay. 
Target Primer Sequences (5’-3’) Primers Reference 
BOX element BOX A1R: CTACGGCAAGGCGACGCTGACG 
(Versalovic et al., 
1994) 
ERIC element
 
ERIC 1: AAGTAAGTGACTGGGGTGAGC 
ERIC 2: ATGTAAGCTCCTGGGGATTCAC 
(Versalovic et al., 
1994) 
Rep element REP 1R: IIIICGICGICATCIGGC 
REP 2F: NCGICTTATCIGGCCTAC 
(Versalovic et al., 
1991) 
 
 
Table II.5. PCR program used for isolates molecular typing. 
 PCR Program timing  
Temperature (ºC) H Number of 
cycles 
95 7’ (x1) 
95 1’ 
(x 30) X 1’ 
65 8’ 
65 16’ (x1) 
X= 53ºC for BOX-PCR; X=52ºC for ERIC-PCR and X=40ºC for REP-PCR. 
 
b. Screening for antibiotic resistance genes 
 AR genes were screened by PCR according to the phenotype given by Vitek® 
Automated System.   
The reaction mixture used for amplification of the AR genes is the same as in 
Table II.2 and the PCR programs that were used are summarized in Table II.3 as A, B 
and C. All reaction conditions for each gene targeted are described in Table II.6. 
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Table II.6. PCR conditions for AR genes amplifications. Programs used are described in table II.3. 
Target Program 
Annealing 
Temperature 
(ºC) 
Primer Sequence (5’-3’) Primers Reference Amplicon 
size (bp) Control Strains 
Control Strains 
Reference 
blaCTX-M B 55 
CTX-M F Lu: SCVATGTGCAGYACCAGTAA 
CTX-M R Lu: GCTGCCGGTYTTATCVCC (Lu et al., 2010) 652 E. coli C65 (Tacão et al., 2012) 
qnrA A 53 
qnrA_F: TTCTCACGCCAGGATTTG 
qnrA_R: CCATCCAGATCGGCAAA (Guillard et al., 2011) 521 
Shewanella 
algae Sh2 
(Tacão et al., 
unpublished 
qnrB A 53 
qnrB_F: GGMATHGAAATTCGCCCACTG 
qnrB_F: TTYGCBGYYCGCCAGTCG 
(Cattoir et al., 2007) 
(Guillard et al., 2011) 261 
K. pneumoniae 
Kp1 (Alves et al., 2014) 
qnrS A 54 
qnrS_F: GCAAGTTCATTGAACAGGGT 
qnrS_R: TCTAAACCGTCGAGTTCGGCG (Cattoir et al., 2007) 428 K. oxytoca Ko25 (Alves et al., 2014) 
aac(6’)-
ib B 54 
Aac-6’-ib_F: TTGCGATGCTCTATGAGTGGCTA 
Aac-6’-ib_R: CTCGAATGCCTGGCGTGTTT (Park et al., 2006) 482 - - 
sul1 A 50 
Sul1_F: CTG AACGATATCCAAGGATTYCC 
Sul1_R: AAAAATCCCACGGRTC (Heuer & Smalla, 2007) 239 
Aeromonas 
media (Alves et al., 2014) 
sul2 A 60 
Sul2_F: GCGCTCAAGGCAGATGGCAT 
Sul2_R: GCGTTTGATACCGGCACCCG (Henriques et al., 2006) 293 E. coli A237 (Alves et al., 2014) 
blaTEM C 60 
MultiTEM_For: CATTTCCGTGTCGCCCTTATTC 
MultiTEM_Rev: CGTTCATCCATAGTTGCCTGAC (Dallenne et al., 2010) 800 E. coli A237 (Alves et al., 2014) 
blaSHV C 60 
MultiSHV_For: AGCCGCTTGAGCAAATTAAAC 
MultiSHV_Rev: ATCCCGCAGATAAATCACCAC (Dallenne et al., 2010) 713 E. coli A237 (Alves et al., 2014) 
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c. Detection of blaAmpC-Like genes 
 Detection of plasmid-mediated AmpC-Like β-lactamases coding genes was 
performed by multiplex PCR, according to (Dallenne et al., 2010). The PCR program 
used is listed in Table II.3 as PCR Program C. 
   Primers and respective concentrations are summarized in Table II.7. The reaction 
mixture differed from the one in Table II.2, since the search of blaAmpC-Like genes is carried 
out by a multiplex PCR, and it is presented in Table II.8. 
 
Table II.7. Primers and respective concentrations for blaAmpC-Like genes. 
Target Primer Sequences 
Amplicon Size 
(bp) 
[Primers] 
(pmol/ μL) 
blaACC ACC_F:CACCTCCAGCGACTTGTTAC ACC_R:GTTAGCCAGCATCACGATCC 346 0.2 
blaFOX FOX_F:CTACAGTGCGGGTGGTTT FOX_R:CTATTTGCGGCCAGGTGA 162 0.5 
blaMOX MOX_F:GCAACAACGACAATCCATCCT MOX_R:GGGATAGGCGTAACTCTCCCAA 895 0.2 
blaDHA DHA_F: TGATGGCACAGCAGGATATTC DHA_R: GCTTTGACTCTTTCGGTATTCG 997 0.5 
blaCIT CIT_F: CGAAGAGGCAATGACCAGAC CIT_R: ACGGACAGGGTTAGGATAGY 538 0.2 
blaEBC EBC_F: CGGTAAAGCCGATGTTGCG EBC_R: AGCCTAACCCCTGATACA 683 0.2 
 
 
Table II.8. Reaction mixture for blaAmpC-Like genes Multiplex PCR. 
Sample reaction mixture  Volume (µL) 
Mix NzyTech 
(2.5mM MgCl2; 200µM dNTPs; 0.2U/µL DNA Polymerase) 6.25 
Primer F MOX (10µM) 0.50 
Primer R MOX (10µM) 0.50 
Primer F CIT (10µM) 0.50 
Primer R CIT (10µM) 0.50 
Primer F FOX (10µM) 1.25 
Primer R FOX (10µM) 1.25 
Primer F ACC (10µM) 0.50 
Primer R ACC (10µM) 0.50 
Primer F DHA (10µM) 1.25 
Primer R DHA (10µM) 1.25 
Primer F EBC (10µM) 0.50 
Primer R EBC (10µM) 0.50 
DNA (50-100ng/µL) 1.00 
dH2O 8.75 
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d. Determination of genomic context of antibiotic resistance 
genes 
Genomic context of the detected AR genes was investigated by analyzing the 
regions surrounding these genes. This was performed by PCR and subsequent sequencing 
of the resulting amplicons. Isolates carrying blaCTX-M and blaCMY genes were 
characterized. blaCTX-M-positive isolates were characterized by inspecting for the 
presence of the ISEcp1 insertion sequence upstream of the gene, and downstream by the 
presence of orf477. blaCMY-positive isolates were tested for ISEcp1, located upstream of 
the gene. The reaction mixture used for the determination of the genomic context is the 
one listed in Table II.2 and Table II.9 describes PCR conditions and primers used for 
characterization of these regions. 
 
Table II.9. PCR conditions and primers used to characterize AR genes surrounding regions. 
Target Program 
Annealing 
Temperature 
(ºC) 
Primer Sequence (5’-3’) Primer Reference 
ISEcp1
 
D 52 ISEcp1_U1_F: AAAAATGATTGAAAGGTGGT CTX_R Lu: GCTGCCGGTYTTATCVCC 
(Saladin et al., 2002) 
(Lu et al., 2010) 
D 52 ISEcp1_U1_F: AAAAATGATTGAAAGGTGGT CIT_R: ACGGACAGGGTTAGGATAGY 
(Saladin et al., 2002) 
(Dallenne et al., 2010) 
IS26 D 52 IS26U: AGCGGTAAATCGTGGAGTGA CTX_R Lu: GCTGCCGGTYTTATCVCC 
(Saladin et al., 2002) 
(Lu et al., 2010) 
orf477 D 52 CTX_F Lu: SCVATGTGCAGYACCAGTAA Orf477_R: ACTTCAAAAATTATGCCACC 
(Lu et al., 2010) 
(Eckert et al., 2006) 
 
 
e. Determination of integrase genes and integron gene arrays 
The presence of integrase genes was evaluated by searching the genes intI1 and 
intI2, which code for class 1 and 2 integrases, respectively. The integron content was also 
characterized for the isolates that harbored the intI1 and/or intI2 genes. This was done by 
PCR and subsequent sequencing reaction of the resulting amplicons. The reaction mixture 
used is present in Table II.2. Table II.10 describes PCR conditions and primers used to 
characterize integrase genes and the integrons’ arrays. 
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Table II.10. PCR conditions and primers used to characterize integrase genes and surrounding regions. 
Target Program 
Annealing 
Temperature 
(ºC) 
Primer Sequence (5’-3’) Amplicon 
size (bp) 
Primers 
Reference 
intI1 
gene
 
A 55 IntI1_F: CCTCCCGCACGATGATC 
IntI_R: TCCACGCATCGTCAGGC 
280 
(Kraft et al., 
1986) 
intI2 
gene 
A 50 IntI2_F: TTATTGCTGGGATTA GGC 
IntI2_R: ACGGCTACCCTCTGTTATC 
233 (Goldstein et 
al., 2001) 
Content 
of class 1 
integrons 
E 55 5’CS: GGCATCCAAGCAGCAAG 3’CS: AAGCAGACTTGACCTGA 
Variable 
(Levesque et 
al., 1995) 
F 52 IntI1_F: CCTCCCGCACGATGATC 3’CS: AAGCAGACTACTTGACCTGA 
(Kraft et al., 
1986) 
(Levesque et 
al., 1995) 
Content 
of class 2 
integrons 
E 55 Hep F: CGGGATCCCGGACGGCATGCACGATTTGTA Hep R: GATGCCATCGCAAGTACGAG Variable 
(White et al., 
2001) 
 
 
 4. DNA electrophoresis and visualization 
PCR products were separated by electrophoresis at 80V for 1h20 for confirming 
DNA extraction, detection of AR genes and genomic context, and 2h45 for molecular 
typing. PCR products were loaded on a Seakem® LE Agarose (Lonza, USA) gel 1x TAE 
(5Prime, Deutschland), of 0.8% (w/v) for DNA extraction and 1.5% (w/v) for the 
remaining experiments. In each gel was loaded the molecular weight marker 
GeneRuller™ DNA Ladder Mix (MBI Fermentas, Lithuania). 
For visualization, the gels were stained with a solution of 0.5 µg/mL ethidium 
bromide (Sigma, USA) for 10-15 minutes and washed in dH2O for 15-20 minutes. Gel 
images were obtained using Molecular Imager® GelDoc™ XR+ System (Bio-Rad, USA) 
under UV light. 
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 5. PCR products sequencing  
Products resulting from the PCR experiments were used as template in the 
sequencing reaction carried out by GATC Company (Germany). 
The final sequences were visualized and edited with FinchTV program (Geopiza, 
USA). Similarities were searched using BLAST software at the National Biotechno logy 
Information (NCBI) website against sequence databases. 
 
 6. Conjugation experiments  
 Conjugation assays were performed for strains containing blaCTX-M genes and for 
strains containing blaAmpC genes. For blaCTX-M genes, from 18 isolates containing these 
genes, only 8 were used as donors based on their resistance phenotype to cefotaxime. 
These donors were previously identified as M. morganii (n=6) and C. freundii (n=2) 
carrying blaCTX-M-15 variant. For blaAmpC genes, the resistance phenotype to cefotaxime 
also reduced the number of donors, in this case, from 11 to 7 isolates, from which: E. coli 
(n=6) and E. aerogenes (n=1), carrying blaCMY genes. The rifampicin resistant E. coli 
CV601 was used as recipient strain. Conjugation protocol is described below. 
Resulting transconjugants were selected in Plate Count Agar (PCA) plates 
supplemented with rifampicin (150 mg/mL) and cefotaxime (4 mg/mL). To confirm the 
identity of the transconjugant and the acquisition of the plasmid, BOX-PCR and detection 
of blaCTX-M and blaCMY genes was performed as described above. Upon the confirma tion 
of the transconjugant, genomic characterization was performed in order to identify the 
genes previously found in the donor isolate. 
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Conjugation Protocol 
Day 1: Overnight grow of donors and recipient strains in 6 mL of LB (Merck, Germany)   
broth. 
Adjust the optical density (OD) at 600nm in a way that it falls between 0.6-0.8. 
Place donors and recipient strains in selective plates for ŵutaŶts’ rate 
evaluation. 
Day 2: Mix 900 µL of donor cells and 900 µL of recipient cells culture (1:1 ratio). 
               Centrifuge at 10.000 rpm for 5 minutes at room temperature.  
               Discard liquid and add 1 mL of fresh LB medium. 
               Incubate overnight, without shaking, at 37ºC. 
Day 3: Centrifuge at 10.000 rpm for 5 minutes at room temperature. 
              Resuspend cells in 1 mL of NaCl 0.9%. 
              Inoculate directly (100) in plates with antibiotics or dilute:  
  10-1: dilute 100 µL of 100 in 900 µL of NaCl 0.9%; 
  10-2: dilute 100 µL of 10-1 in 900 µL of NaCl 0.9%. 
 Spread 100 µL of each in plates with antibiotics.  
Day 4: Incubate overnight, at 37ºC or 28ºC.  
 
 
 7. Plasmid DNA extraction  
 Plasmid DNA, from donor cells that gave a positive result in the conjugation 
experiment and respective transconjugant, was extracted with E.Z.N.A.® Plasmid Mini 
Kit II (Omega, bio-tek, USA). The protocol used was Spin Protocol and it is described 
below. 
 An alteration was performed on step 22 of the protocol. Instead of using 80-100µL 
of Elution Buffer, plasmid DNA was eluted in 40µL of Elution Buffer.  
 
 
 
 
 
 
 
 
 
 
36 
 
E.Z.N.A.® Plasmid Mini Kit II – Spin Protocol 
1. Isolate a single colony from freshly streaked selective plate, and inoculate a culture 
of 10-15mL (50µg/mL) LB medium containing the appropriate selective antibiotic. 
Incubate for ~12-16 hours at 37ºC with vigorous shaking (~300rpm). Use culture 
tube or a flask with a volume at least 4 times the volume of the culture. It is strongly 
recommended that an end A negative strain of E. coli be used for routine plasmid 
isolation.   
2. Centrifugation at 5,000 x g for 10 minutes at room temperature. 
3. Decant or aspirate the medium and discard. 
4. Add 500µL Solution I/RNase A. Vortex or pipet up and down to mix it thoroughly. 
Complete resupension of cell pellet it vital for obtaining good yields.  
5. Transfer suspension into new 2mL microcentrifuge tube. 
6. Add 500µL of Solution II. Invert and gently rotate the tube several times to obtain a 
clear lysate. A 2-3 minutes incubation may be necessary.  
7. Add 700µL Solution III. Immediately invert several times until a flocculent white 
precipitate forms. 
8. Centrifuge at ŵaxiŵuŵ speed ;шϭϯ,000 x g) for 10 minutes at room temperature. A 
compact white pellet will form.  Promptly proceed to the next step.  
9. Insert a HiBind® DNA Mini Column into a 2mL Collection Tube. 
Optional Protocol for Column Equilibration: 
 1. Add 100µL 3M NaOH to the HiBind® DNA Mini Column. 
 2. Centrifuge at maximum speed for 30-60 seconds. 
 3. Discard the filtrate and reuse the collection tube. 
10.  Transfer 700µL cleared lysate from step 8 CAREFULLY aspirating it into the HiBind® 
DNA Mini Column. Be careful not to disturb the pellet and that no cellular debris is 
transferred to the HiBind® DNA Mini Column. 
11.  Centrifuge at maximum speed for 1 minute. 
12.  Discard the filtrate and reuse the collection tube. 
13.  Repeat steps 10-12 until all cleared lysate has been transferred to the HiBind® DNA 
Mini Column. 
14.  Add 500µL HBC Buffer. 
15.  Centrifuge at maximum speed for 1 minute. 
16.  Discard the filtrate and reuse collection tube. 
17.  Add 700µL DNA Wash Buffer. 
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18.  Centrifuge at maximum speed for 1 minute. 
19.  Discard the filtrate and reuse collection tube. 
Optional: Repeat steps 17-19 for a second DNA Wash Buffer wash step. 
20.  Centrifuge the empty HiBind® DNA Mini Column for 2 minutes at maximum speed 
to dry the column matrix.  
21.  Transfer the HiBind® DNA Mini Column to a clean 1,5mL microcentrifuge tube.  
22.  Add 40µL Elution Buffer directly to the center of the column membrane.  
23.  Let sit at room temperature for 1 minute. 
24.  Centrifuge at maximum speed for 1 minute. 
25.  Store DNA at -20ºC. 
 
 
 8. Replicon typing 
 Detection of IncA/C, IncB/O, IncF (FIA, FIB, FIC, FIIA, Frep subgroups), 
IncHI1, IncHI2, IncI1, IncK, IncX, IncL/M, IncN, IncP, IncT, IncW and IncY replicons 
was performed by simplex PCR for Frep subgroup and multiplex PCR for the remaining 
groups, according to the PCR-based inc/rep typing method developed by Alessandra 
Carattoli et al. (Carattoli et al., 2005). The PCR program used for this amplification is 
listed in Table II.3 as Program G and the annealing temperatures were 60ºC and 52ºC for 
the multiplex and simplex PCR, respectively. Reaction conditions and primers are 
summarized in Table II.11 and Table II.12, respectively. Positive controls used in replicon 
typing assay are cloned amplicons and were gently given by Alessandra Carattoli 
(Carattoli et al., 2005).  
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Table II.11. Reaction mixture for blaAmpC-Like genes Multiplex PCR. 
 Volume (µL) 
Sample Reaction Mixture  Multiplex 1 Multiplex 2 Multiplex 3 Simplex 1 
Mix NzyTech 
(2.5mM MgCl2; 200µM dNTPs; 0.2U/µL 
DNA Polymerase) 
6.25 6.25 6.25 6.25 
Primer F A/C (10µM) 1.00 - - - 
Primer R A/C (10µM) 1.00 - - - 
Primer F FIC (10µM) 1.00 - - - 
Primer R FIC (10µM) 1.00 - - - 
Primer F P (10µM) 1.00 - - - 
Primer R P (10µM) 1.00 - - - 
Primer F T (10µM) 1.00 - - - 
Primer R T (10µM) 1.00 - - - 
Primer R B/O (10µM) 1.00 - - - 
Primer F K/B (10µM) 1.00 1.00 - - 
Primer R K (10µM) - 1.00 - - 
Primer F W (10µM) - 1.00 - - 
Primer R W (10µM) - 1.00 - - 
Primer F FIIA (10µM) - 1.00 - - 
Primer R FIIA (10µM) - 1.00 - - 
Primer F FIA (10µM) - 1.00 - - 
Primer R FIA (10µM) - 1.00 - - 
Primer F FIB (10µM) - 1.00 - - 
Primer R FIB (10µM) - 1.00 - - 
Primer F Y (10µM) - 1.00 - - 
Primer R Y (10µM) - 1.00 - - 
Primer F I1 (10µM) - - 1.00 - 
Primer R I1 (10µM) - - 1.00 - 
Primer F X (10µM) - - 1.00 - 
Primer R X (10µM) - - 1.00 - 
Primer F HI1 (10µM) - - 1.00 - 
Primer R HI1 (10µM) - - 1.00 - 
Primer F HI2 (10µM) - - 1.00 - 
Primer R HI2 (10µM) - - 1.00 - 
Primer F N (10µM) - - 1.00 - 
Primer R N (10µM) - - 1.00 - 
Primer F L/M (10µM) - - 1.00 - 
Primer R L/M (10µM) - - 1.00 - 
Primer F Frep (10µM) - - - 1.00 
Primer R Frep (10µM) - - - 1.00 
H20 13.75 5.75 5.75 15.75 
Cell suspension (0.5 McFarland) 1.00 1.00 1.00 1.00 
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Table II.12. .Reaction conditions and primers  used for the detection of plasmid Inc groups. 
Target Primer Sequences (5’-3’) (Carattoli et al., 2005)  
Amplicon 
size (bp) PCR Group  
A/C A/C F: GAGAACCAAAGACAAAGACCTGGA 
A/C R: ACGACAAACCTGAATTGCCTCCTT 
465 
Multiplex 1 
FIC FIC F: GTGAACTGGCAGATGAGGAAGG 
FIC R: TTCTCCTCGTCGCCAAACTAGAT 
262 
P P F: CTATGGCCCTGCAAACGCGCCAGAAA 
P R: TCACGCGCCAGGGCGCAGCC 
534 
T T F: TTGGCCTGTTTGTGCCTAAACCAT 
T R: CGTTGATTACACTTAGCTTTGGAC 
750 
B/O B/O R: TCTGCGTTCCGCCAAGTTCGA 159 
K/B K/B F: GCGGTCCGGAAAGCCAGAAAAC 
K R: TCTTTCACGAGCCCGCCAAA 
160 
Multiplex 2 
W W F: CCTAAGAACAACAAAGCCCCCG 
W R: GGTGCGCGGCATAGAACCGT 
242 
FIIA FIIS F: CTGTCGTAAGCTGATGGC 
FIIS R: CTCTGCCACAAACTTCAGC 
270 
FIA FIA F: CCATGCTGGTTCTAGAGAAGGTG 
FIA R: GTATATCCTTACTGGCTTCCGCAG 
462 
FIB FIB F: GGAGTTCTGACACACGATTTTCTG 
FIB R: CTCCCGTCGCTTCAGGGCATT 
702 
Y Y F: AATTCAAACAACACTGTGCAGCCTG 
Y R: GCGAGAATGGACGATTACAAAACTTT 
765 
I1 I1 F: CGAAAGCCGGACGGCAGAA 
I1 R: TCGTCGTTCCGCCAAGTTCGT 
139 
Multiplex 3 
 
X X F: AACCTTAGAGGCTATTTAAGTTGCTGAT 
X R: TGAGAGTCAATTTTTATCTCATGTTTTAGC 
376 
HI1 HI1 F: GGAGCGATGGATTACTTCAGTAC 
HI1 R: TGCCGTTTCACCTCGTGAGTA 
471 
HI2 HI2 F: TTTCTCCTGAGTCACCTGTTAACAC 
HI2 R: GGCTCACTACCGTTGTCATCCT 
644 
N N F: GTCTAACGAGCTTACCGAAG 
N R: GTTTCAACTCTGCCAAGTTC 
559 
L/M L/M F: GGATGAAAACTATCAGCATCTGAAG 
L/M R: CTGCAGGGGCGATTCTTTAGG 
785 
Frep Frep F: TGATCGTTTAAGGAATTTTG 
Frep R: GAAGATCAGTCACACCATCC 
270 Simplex 1 
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III. RESULTS 
1. Molecular typing 
The 46 isolates, obtained from different human biological samples and wards in 
the Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga, E.P.E., were obtained 
in the scope of a previous work and were selected for analysis based on the suspicion of 
β-lactamase production provided by the Vitek2® Automatic System. After the species 
identification, the 46 clinical isolates, identified as: Citrobacter freundii (n=2), 
Escherichia coli (n=16), Enterobacter aerogenes (n=6), Enterobacter cloacae (n=3), 
Morganella morganii (n=17), Providencia stuartii (n=1), Serratia marcescens (n=1), 
were typed to assess the genetic relatedness between them.  
Molecular typing was done by BOX-, ERIC- and REP-PCR (rep-PCR). Figure 
III.1 represents the electrophoresis result of the ERIC-PCR. Upon the combined analysis 
of the fingerprints using the software GelCompar II ®, the resulting dendrogram (Figure 
III.2) was evaluated to assess de genetic diversity of the collection. Isolates displaying 
fingerprints with more than 95% similarity were considered clonal.  
 In general, the isolates clustered according to their phylogenetic affiliation, in 
accordance to the species identification given by Vitek2® automated system. M. morganii 
isolates grouped in one cluster, exhibiting less than 50% similarity with other clusters. E. 
coli and E. aerogenes isolates also grouped in a distinct cluster (less than 40% similar ity 
with other clusters). However, for isolates ER17 (E. cloacae), ER46 (P. stuartii) and 
ER12 (S. marcescens), their grouping was not evident, appearing in different clusters. 
There is a high diversity between isolates among the different clusters, composed by the 
species present in the collection. A total of 45 different patterns were detected, since 
isolates ER42 and ER44 were considered to derive from the same strain based on the 95% 
similarity cutoff. Despite this consideration, both isolates were included in all tests 
performed in this study.    
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M  1   2   3    4   5    6   7   8   9   10  11  12  13  14  15 16  17  18  19  20  21  22 23  24  M 
M 25 26 27 28 29 30  31 32  33 34 35 36 37 38 39 40 41  42 43 44  45 46 C-  C- M  
Figure III.1 – DNA fingerprtins obtained with ERIC-PCR method. M – DNA molecular marker; 1-46 – Clinical 
isolates; C— – negative control.  
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Figure III.2 – Dendrogram showing genetic relatedness of all 46 isolates determined by analysis of rep-PCR 
fingerprint patterns using Dice similarity coefficient and UPGMA cluster methods. Circled identifications 
correspond to the isolates with origin in the community.   
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2. Antibiotic resistance genes  
 The presence of clinically relevant AR genes was confirmed by PCR amplifica t ion 
using primers whose gene targets are conserved regions. The choice of these genes relied 
on the resistance phenotype given by Vitek2® for a certain range of antibiotics, belonging 
to the following families: penicillins, 2nd and 3rd generation cephalosporins, carbapenems,  
fluoroquinolones, sulfamethoxazole/trimethoprim, aminoglycosides and nitrofuranto in. 
Based on this information, PCR analysis was performed in order to detect the presence of 
genes that are known to confer resistance phenotype to these antibiotics. Table III.1 
summarizes genes tested for each antibiotic family.  
  
 
Table III.1. List of tested genes according to the resistance phenotype given by Vitek2® Automated System.  
Antibiotic families Tested Genes 
Penicillins 
(AMP, AMC, TZP) 
 
3rd generation cephalosporins 
(CAZ, CTX) 
blaSHV 
blaTEM 
3rd generation cephalosporins 
(CAZ, CTX) 
blaCTX-M 
blaAmpC 
Fluoroquinolones  
(CIP, LVX) 
qnrA 
qnrB 
qnrS 
aac(6’)-ib-cr  
Sulfamethoxazole/ 
trimethoprim 
(SXT) 
sul1 
sul2 
  
Results obtained by PCR screening of the AR genes referred above, along with 
the resistance phenotypes given by Vitek2®, are presented in Table III.2. 
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Table III.2. Characterization of clinical Enterobacteriaceae isolates: antibiotic resistance phenotypes and genotypes, presence of integrases and integron content. 
Isolate Species Resistance Phenotype  
β-lactamases genes Fluoroquinolones R genes aac(6’)-ib 
gene 
Sulfonamides R 
genes Integrase Gene cassettes arrayb 
blaTEM blaSHV blaCTX-M blaAmpC qnrA qnrB qnrS sul1 sul2 
ER1 E. coli AMC, AMP + - - - - - - + - - 1 NDc 
ER2 M. morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  + - + DHA - - - + + - 1 dfrA15 
ER3 E. coli AMC, AMP, TZP, CAZ, CTX, CIP, LVX, SXT + - - - - - - + - - 1 dfrA15 
ER4 M. morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  + - - DHA - - - + + - 1 dfrA15 
ER5 M. morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  + - + DHA - - - + + - 1 dfrA15 
ER6 E. coli AMC, AMP, CIP, LVX, SXT  + - + - - - - + + - 1 dfrA17, aadA5 
ER7 M. morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  + - - DHA - - - + + + 1 hyp prot, dfrA12, aadA2 
ER8 E. coli AMC, AMP, CAZ, CTX, LVX, SXT  + - - CMY - - - + + + 1 ND 
ER9 E. cloacae AMC, AMP + - - CMY - - - + - - 1 ND 
ER10 E. aerogenes AMC, AMP + - - - - - - + - - 1 ND 
ER11 E. coli AMC, AMP, CAZ, CTX + - - CMY - - - + - - 1 ND 
ER12 S. marcescens Unknown + - - - - - - + - - 1 ND 
ER13 C. freundii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  + - + CMY - + - aacA4cr d + + 1 ND 
ER14 M. morganii AMC, AMP, CIP, LVX + - - DHA - - - + + - 1 aadB 
ER15 E. coli AMC, AMP, CAZ, CTX + - - - - - - + + - 1 ND 
ER16 E. aerogenes AMC, AMP, CAZ, CTX + - - - - - - + - - 1 ND 
ER17 E. cloacae AMC, AMP + - - EBC - - - + - - 1 ND 
ER18 M. morganii AMC, AMP, CAZ, CTX, CIP , LVX, SXT + - + DHA - - - + + - 1 dfrA15 
ER19 E. coli AMC, AMP, CIP, LVX, SXT + - + DHA - - - + - - 1 ND 
ER20 M. morganii Unknown + - + DHA - - - + - - 1 dfrA15 
ER21 M. morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT + - + DHA - - - + + + 1 ND 
ER22 M. morganii Unknown + - + DHA - - - + + - 1 dfrA15 
ER23 M. morganii AMC, AMP, CAZ, CTX, CIP , LVX, SXT + - + DHA - - - + + - 1 aadB, catB3 
ER24 M. morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT + - + DHA - - - + + + 1 dfrA12, hyp prot, aadA2 
ER25 E. aerogenes Unknown + + - - - - - + - - -  
ER26 E. coli AMC, AMP, CAZ, CTX + - - CMY - - - + - - -  
ER27 M. morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT  + - + DHA - - - + + - 1 dfrA15 
ER28 C. freundii AMC, AMP, TZP,CAZ, CTX, CIP, LVX, SXT + + + - + - - + + + 1, 2 ND; dfrA1, sat2, aadA1 
ER29 M. morganii AMC, AMP, CAZ, CTX, CIP , LVX + + + DHA - - - + - - -  
ER30 M. morganii AMC, AMP, CAZ, CTX, CIP, LVX, SXT + - + DHA - - - + + - 1 dfrA15 
ER31 E. coli AMC, AMP, CAZ, CTX + - - CMY - - - - - - -  
ER32 M. morganii AMC, AMP, TZP, CAZ, CTX, CIP, LVX, SXT + - - DHA - - - + + - 1 aadB 
ER33 E. coli AMC, AMP, TZP, CAZ, CTX + - - CMY - - - + - + 1 ND 
ER34 M. morganii AMC, AMP, TZP, CAZ, CTX, CIP, LVX, SXT + - + DHA - - - + + - 1 dfrA15 
ER35 E. coli AMC, AMP, CAZ, CTX + - + - - - - + - - 1 dfrA15 
(continued on the next page) 
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 Table III.2. (continued)  
aAntibiotic abbreviations: AMC, amoxicillin/clavulanic acid; AMP, ampicillin; TZP, piperacillin/tazobactam; CAZ, ceftazidime; CTX, cefotaxime; CIP, ciprofloxacin; LVX, levofloxacin; SXT, 
trimethoprim/sulfamethoxazole. 
b Gene cassettes identified by nucleotide sequencing and comparison against the sequences available in GenBank database using BLAST software. 
c ND, not detected; + and -, indicate gene presence and absence, respectively. 
d
 aacA4cr or aac(6’)-ib-cr  –gene coding the aminoglycoside acetyltransferase variant, aac(6’)-ib-cr , which confers resistance to fluoroquinolones. 
    
  
  
 
Isolate Species Resistance Phenotype a 
β-lactamases genes Fluoroquinolones R genes aac(6’)-ib gene 
Sulfonamides R 
genes Integrase  Gene cassettes array 
blaTEM blaSHV blaCTX-M blaAmpC qnrA qnrB qnrS  sul1 sul2   
ER36 E. coli AMC, AMP, CAZ, CTX, LVX + - + - - - - + - - -  
ER37 E. cloacae AMC, AMP, CAZ, CTX + - - - - - - + - - -  
ER38 M. morganii AMC, AMP, CAZ, CTX, CIP, LVX + - - DHA - - - + + - 1 aadB 
ER39 E. coli AMC, AMP, TZP, CAZ, CTX, CIP, LVX, SXT + - - CMY - - - + - + 1 ND 
ER40 E. coli AMC, AMP, TZP, CIP, LVX + - - - - - - + - + -  
ER41 E. coli AMC, AMP, TZP, CIP, LVX + - - CMY - - - + - - -  
ER42 E. aerogenes AMC, AMP, TZP,CAZ, CTX + - - - - - - - - - -  
ER43 E. coli AMC, AMP, TZP, CAZ, CTX + - - CMY - - - + - - -  
ER44 E. aerogenes AMC, AMP, TZP,CAZ, CTX + - - CMY - - - + - + -  
ER45 E. aerogenes AMC, AMP, TZP, CAZ, CTX - - - - - - - + - - -  
ER46 P. stuartii AMC, AMP, CAZ, CTX, CIP, LVX, SXT + - - - - - - + + + 1 ND 
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Isolates displaying resistance to penicillins and 3rd generation cephalosporins were 
tested for blaTEM, blaSHV, blaCTX-M and blaAmpC presence.  The gene blaTEM was the most 
frequently detected, present in 45 isolates. blaSHV gene was only present in 3 isolates 
identified as E. aerogenes, M. morganii and C. freundii. The presence of blaCTX-M gene 
was detected in 18 isolates from which: M. morganii (n=12), E. coli (n=4) and C. freundii 
(n=2). The strategy used to search for the presence of blaAmpC genes allowed the 
distinction among the AmpC β-lactamases types. blaAmpC genes were detected in a total 
of 30 isolates from which: blaDHA (n=18) in isolates of E. coli (n=1) and isolates of M. 
morganii (n=17), blaEBC (n=1) in 1 isolate of E. aerogenes, blaCMY (n=11) in isolates of 
E. coli (n=8), E. aerogenes (n=1), E. cloacae (n=1), C. freundii (n=1). 
All isolates were tested for genes that confer resistance or at least reduce the 
susceptibility to fluoroquinolones, namely: qnrA, qnrB and qnrS. qnrA gene was found 
only in one C. freundii as well as qnrB, although in distinct isolates. Gene qnrS was absent 
in all 46 Enterobacteriaceae isolates. aac(6’)-ib-cr  is a variant of an aminoglycos ide 
acetyltransferase, coded by aac(6’)-ib-cr  gene, that has the ability to modify certain 
quinolones. aac(6’)-ib gene was present in 44 isolates belonging to all 7 identified 
species. Only isolate ER13 was sequenced and it was confirmed that it harbors aac(6’)-
ib-cr  gene variant. For the remaining isolates, the variant was not confirmed.  
sul1 and sul2 genes were present in 21 and 11 isolates, respectively. sul1 was 
present in M. morganii (n=15), E. coli (n=3), C. freundii (n=2) and P. stuartii (n=1). sul2 
was present in less isolates than sul1, from which: M. morganii (n=3), E. coli (n=4), C. 
freundii (n=2), E. aerogenes (n=1) and P. stuartii (n=1). A total of 9 isolates harbor both 
sul1 and sul2 genes. 
 
 2.1. Genomic context and variant of the blaCTX-M and blaCMY genes 
Isolates carrying blaCTX-M and blaCMY genes were characterized in order to 
evaluate their genomic context. Sequencing analysis of the PCR amplicons provided the 
information about the gene variant.  
The presence of the ISEcp1 insertion sequence upstream of the blaCTX-M gene and 
the presence of orf477 downstream was searched in blaCTX-M-positive isolates. From 18 
blaCTX-M-positive isolates, 17 were positive for the presence of ISEcp1 upstream of the 
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gene and orf477 downstream. Using BLAST software, the gene variant was confirmed to 
be blaCTX-M-15 in all 17 isolates. Figure III.3 represents the genomic context of blaCTX-M-15. 
The isolate ER6 is the only one for which the upstream region and the gene variant 
are unknown, only the downstream region is known – orf477 is present. For this isolate, 
amplification between ISEcp1 and the blaCTX-M gene gave a negative PCR result. Another 
possible context was tested, namely, the presence of IS26 insertion sequence. Although 
the PCR amplification resulted in a band with a size similar to the positive control, the 
sequencing analysis was not successful and did not allow the characterization of this PCR 
amplicon. 
blaCMY-positive isolates were tested for ISEcp1, located upstream of the gene.  
From 11 blaCMY+ isolates, 6 E. coli isolates gave a positive PCR result for the presence of 
ISEcp1. Figure III.4 represents the genomic context of these 6 E. coli isolates. The 
genomic context of the other 5 isolates, belonging to species E. coli (n=2), C. freundii 
(n=1), E. cloacae (n=1) and E. aerogenes (n=1), remains unknown. With the same 
strategy used for blaCTX-M+ isolates, the gene variant was not known since the blaCMY gene 
was not completely sequenced. Although, the sequence retrieved by the sequencing 
analysis was large enough to identify the variant as part of the CMY-2 group. 
To address this problem, a multiple sequence alignment was performed in 
ClustalOmega (available at: http://www.ebi.ac.uk/Tools/msa/clustalo/) with all amino 
acid sequences of β-lactamases belonging to CMY-2 group available in CARD database 
(available at: https://card.mcmaster.ca/) as well as the sequences from isolates that tested 
positive for blaCMY with the ISEcp1 located upstream the gene (sequences used are 
presented in supplemental material). Results (Figure III.5) indicate that the CMY variant 
can either be CMY-2 or CMY-22.  
 
 
 
Figure III.3 – Genomic context of blaCTX-M-15 positive isolates. ISEcp1, partial sequence; blaCTX-M-15, β-lactamase CTX-
M.15 complete coding sequence; orf477, partial sequence. 
 
 
 
Figure III.4 – Genomic context of blaCMY positive isolates. ISEcp1, partial sequence; blaCMY, β-lactamase CMY-2 or 
CMY-22 partial sequence. 
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48 
 
gi|BAC76072.1|CFE-1        MMKKSICCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAIIYQGKPYY 
gi|CMY-40                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-38                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-12                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-15                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CAA55007.1|LAT-1        MMKKSLCSALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-53                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-20                  -MKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-45                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-36                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|AHW47897.1|CMY-111      MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|AGC54799.1|CMY-95       MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-99                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-59                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-42                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-31                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-30                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-29                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-27                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-25                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-24                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-23                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-21                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-16                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-14                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-7                   MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-6                   MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-5                   MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-4                   MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|AGC54798.1|CMY-94       MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-44                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-33                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-22                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-18                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-2                   MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
ER8                        MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
ER11                       MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
ER26                       MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
ER31                       MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
ER33                       MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
ER39                       MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-49                  MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAIIYQGKPYY 
gi|AGZ20169.1|CMY-108      MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYY 
gi|CMY-13                  MMKKSLCCALLLTASFSTFASAKTEQQIADIVNRTITPLMQEQAIPGMAVAIIYQGKPYY 
gi|CMY-26                  MMKKSLCCALLLTASFSTFASAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKTYY 
                            ****:*.************:******************************:***** ** 
 
gi|BAC76072.1|CFE-1        FTWGKADIANNRPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTQYWPELTGKQ 
gi|CMY-40                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-38                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-12                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-15                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CAA55007.1|LAT-1        FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDCIARGEIKLSDPVTKYWPELTGKK 
gi|CMY-53                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-20                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-45                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-36                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDCIARGEIKLSDPVTKYWPELTGKQ 
gi|AHW47897.1|CMY-111      FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|AGC54799.1|CMY-95       FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-99                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-59                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-42                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-31                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-30                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-29                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-27                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-25                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-24                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-23                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-21                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-16                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-14                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-7                   FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-6                   FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-5                   FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKFSDPVTKYWPELTGKQ 
gi|CMY-4                   FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|AGC54798.1|CMY-94       FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
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gi|CMY-44                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-33                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-22                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-18                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-2                   FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
ER8                        FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
ER11                       FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
ER26                       FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
ER31                       FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
ER33                       FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
ER39                       FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-49                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|AGZ20169.1|CMY-108      FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-13                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
gi|CMY-26                  FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQ 
                           ***********:************************.*******:*****:********: 
 
gi|BAC76072.1|CFE-1        WQGISLLHLATYTAGGLPLQVPDDVTDKAALLRFYQNWQPQWAPGAKRLYANSSIGLFGA 
gi|CMY-40                  WQGISLLHLATYTAGGLPLQIPDDVTDKAALLRFYQNWQPQWTPGAKRLYANSSIGLFGT 
gi|CMY-38                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-12                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYSNSSIGLFGA 
gi|CMY-15                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CAA55007.1|LAT-1        WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-53                  WQGICLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-20                  WQGISLLHLATYTAGGLPLQIPDDVTDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-45                  WQGIRLLHLATYTAGGLPLKIPDDVRDKAALLHFYQNWQPQWTPGAKRLYSNSSIGLFGA 
gi|CMY-36                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|AHW47897.1|CMY-111      WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|AGC54799.1|CMY-95       WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-99                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYSNSSIGLFGA 
gi|CMY-59                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-42                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-31                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-30                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-29                  WQGIRLLHLATYTAGGLPLQFPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGE 
gi|CMY-27                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-25                  WQGIRLLHLATYTAGGLPLQIPDDVTDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-24                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-23                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-21                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGE 
gi|CMY-16                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYSNSSIGLFGA 
gi|CMY-14                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-7                   WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGE 
gi|CMY-6                   WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-5                   WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-4                   WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|AGC54798.1|CMY-94       WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-44                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-33                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-22                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-18                  WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-2                   WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
ER8                        WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
ER11                       WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
ER26                       WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
ER31                       WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
ER33                       WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
ER39                       WQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|CMY-49                  WQGISLLHLATYTAGGLPLQIPDDVTDKAALLRFYQNWQPQWTPGAKRLYANSSIGLFGA 
gi|AGZ20169.1|CMY-108      WQGISLLHLATYTAGGLPLQIPDDVTDKAALLRFYQNWQPQWAPGAKRLYANSSIGLFGA 
gi|CMY-13                  WQGISLLHLATYTAGGLPLQIPDDVTDKAALLRFYQNWQPQWAPGAKRLYANSSIGLFGA 
gi|CMY-26                  WQDISLLHLATYTAGGLPLQIPDDVTDKTALLHFYQNWQPQWAPGAKRLYANSSIGLFGA 
                           **.* **************:.**** **:***:*********:*******:********  
 
gi|BAC76072.1|CFE-1        LAVKPSGMSYEEAMTTRVLQPLKLAHTWITVPQSEQKDYALGYREGKPVHVSPGQLDAEA 
gi|CMY-40                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQSEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-38                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSPGQLNAEA 
gi|CMY-12                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSPGQLDAEA 
gi|CMY-15                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSPGQLDAEA 
gi|CAA55007.1|LAT-1        LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGRLDAEA 
gi|CMY-53                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-20                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-45                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSPGQLDAEA 
gi|CMY-36                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPENEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|AHW47897.1|CMY-111      LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDVEA 
gi|AGC54799.1|CMY-95       LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHASPGQLDAEA 
gi|CMY-99                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSPGQLDAEA 
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gi|CMY-59                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHASPGQLDAEA 
gi|CMY-42                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHSSPGQLDAEA 
gi|CMY-31                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGRLDAEA 
gi|CMY-30                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHGSPGQLDAEA 
gi|CMY-29                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-27                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYACGYREGKPVHVSPGQLDAEA 
gi|CMY-25                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-24                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVYVSPGQLDAEA 
gi|CMY-23                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAGA 
gi|CMY-21                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGKLDAEA 
gi|CMY-16                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSPGQLDAEA 
gi|CMY-14                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSPGQLDAEA 
gi|CMY-7                   LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-6                   LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYALGYREGKPVHVSPGQLDAEA 
gi|CMY-5                   LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-4                   LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSPGQLDAEA 
gi|AGC54798.1|CMY-94       LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-44                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-33                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-22                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-18                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-2                   LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
ER8                        LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
ER11                       LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
ER26                       LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
ER31                       LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
ER33                       LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
ER39                       LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-49                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVTPGQLDAEA 
gi|AGZ20169.1|CMY-108      LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQSEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-13                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQLDAEA 
gi|CMY-26                  LAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQSEQKDYAWGYREGKPVHVSPGQLDAEA 
                           *************** ****************:.****** ********: :**:*:. * 
 
gi|BAC76072.1|CFE-1        YGVKSSVVDMTRWVQANMDASQVQEKTLQQGIKLAQSRYWRIGDMYQGLGWEMLNWPVKA 
gi|CMY-40                  YGVKSSVIDMAHWVQANMDASHVQEKTLQQGIELAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-38                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-12                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-15                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CAA55007.1|LAT-1        YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-53                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIELAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-20                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-45                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-36                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|AHW47897.1|CMY-111      YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|AGC54799.1|CMY-95       YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-99                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-59                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-42                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-31                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-30                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-29                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-27                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-25                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-24                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-23                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-21                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-16                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-14                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-7                   YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-6                   YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-5                   YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-4                   YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|AGC54798.1|CMY-94       YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-44                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-33                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-22                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-18                  YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-2                   YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
ER8                        YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
ER11                       YGVKSSVIDMARWVQANMDASHVQEKTLQQGIA--------------------------- 
ER26                       YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
ER31                       YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
ER33                       YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
ER39                       YGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-49                  YGVKSNVTDMARWIQVNMDASRVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|AGZ20169.1|CMY-108      YGVKSSVIDMARWVQVNMDASRVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
51 
 
gi|CMY-13                  YGVKSNVTDMARWVQVNMDASRVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
gi|CMY-26                  YGVKSNVTDMARWVQVNMDASRVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKA 
                           *****.* **::*:*.*****:**********                             
 
gi|BAC76072.1|CFE-1        DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-40                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGYTGGFGSYVAFVPEKNLGIVM 
gi|CMY-38                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-12                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-15                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CAA55007.1|LAT-1        DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-53                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-20                  DSIINGS--DNKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-45                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTVGFGSYVAFVPEKNLGIVM 
gi|CMY-36                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|AHW47897.1|CMY-111      DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|AGC54799.1|CMY-95       DSIINGS--DSKVASAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-99                  DSIINGS--DSKVALAALPAVEVNPPATAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-59                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-42                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-31                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-30                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-29                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-27                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-25                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-24                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-23                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-21                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-16                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-14                  DSIINGS--DSKVALAALPAVEINPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-7                   DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-6                   DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-5                   DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-4                   DSIINGSD--SKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|AGC54798.1|CMY-94       DSIINGSD--SKVASAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-44                  DSIINGSDSK------VAPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-33                  DSIINGSDS----KVAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-22                  DSIING--SDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-18                  DSIINGNGSDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-2                   DSIING--SDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
ER8                        DSIING--SDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI-- 
ER11                       ------------------------------------------------------------ 
ER26                       DSIING--SDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI-- 
ER31                       DSIING--SDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI-- 
ER33                       DSIING--SDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKN----- 
ER39                       DSIING--SDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKN----- 
gi|CMY-49                  DSIINGS--DSKVALAALHTVEVNPPAPAVKASWVHKTGSTGGFGSYVAFIPEKNLGIVM 
gi|AGZ20169.1|CMY-108      DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-13                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
gi|CMY-26                  DSIINGS--DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVM 
                                                                                        
 
gi|BAC76072.1|CFE-1        LANKSYPNPARVEAAWRILEKLQ 
gi|CMY-40                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-38                  LANKNYPNPVRVEAAWRILEKLQ 
gi|CMY-12                  LANKNYPNPVRVEAAWRILEKLQ 
gi|CMY-15                  LANKNYPNPVRVEAAWRILEKLQ 
gi|CAA55007.1|LAT-1        LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-53                  LANKSYPNPARVEAAWRILEKLQ 
gi|CMY-20                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-45                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-36                  LANKSYPNPVRVEAAWRILEKLQ 
gi|AHW47897.1|CMY-111      LANKSYPNPVRVEAAWRILEKLQ 
gi|AGC54799.1|CMY-95       LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-99                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-59                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-42                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-31                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-30                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-29                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-27                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-25                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-24                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-23                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-21                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-16                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-14                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-7                   LANKSYPNPVRVEAAWRILEKLQ 
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gi|CMY-6                   LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-5                   LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-4                   LANKSYPNPVRVEAAWRILEKLQ 
gi|AGC54798.1|CMY-94       LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-44                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-33                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-22                  LANKSYPNPVRVEAYWRILEKLQ 
gi|CMY-18                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-2                   LANKSYPNPVRVEAAWRILEKLQ 
ER8                        ----------------------- 
ER11                       ----------------------- 
ER26                       ----------------------- 
ER31                       ----------------------- 
ER33                       ----------------------- 
ER39                       ----------------------- 
gi|CMY-49                  LANKSYPNPVRVEAAWRILEKLQ 
gi|AGZ20169.1|CMY-108      LANKSYPNPVRVEAAWHILEKLQ 
gi|CMY-13                  LANKSYPNPVRVEAAWRILEKLQ 
gi|CMY-26                  LANKSYPNPVRVEAAWRILEKLQ 
 
Figure III.5 – Results regarding multiple sequence alignment performed in ClustalOmega with all amino acid 
sequences of β-lactamases belonging to CMY-2 group available in CARD database. CMY-2 and CMY-22 sequences 
are highlighted. 
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2.2. Integrase genes and integron gene arrays 
 The presence of integrons was detected by PCR amplification of the integrase 
genes. Results are presented in Table III.2. The integrase gene intI1 was detected in 34 
isolates, identified as C. freundii (n=2), E. coli (n=10), E. aerogenes (n=2), E. cloacae 
(n=2), M. morganii (n=16), P. stuartii (n=1), S. marcescens (n=1). Gene intI2 was only 
detected in 1 C. freundii isolate. This isolate harbors both intI1 and intI2 genes.  
 A total of 35 class 1 and 2 integrons were analyzed for the presence of inserted 
gene cassettes in the variable region with the primers and PCR conditions presented in 
Table II.10. In 15 isolates harboring class 1 integrons, only the presence of the integrase 
gene was determined since the PCR results for the presence of inserted DNA were 
negative. For the remaining integrons, 7 different arrays were detected (Table III.2). The 
majority (n=11) contained dfrA15 gene cassettes, which confers resistance to 
trimethoprim. Other gene cassettes were detected, among them: aadA1, aadA2, aadA5 
and aadB which confer resistance to aminoglycosides, dfrA1, dfrA12 and dfrA17 
(resistance to trimethoprim), catB3, known to confer resistance to chloramphenicol, and 
sat2, conferring resistance to streptothricin. 
 
3. Conjugation experiments 
Conjugation assays were performed for strains containing blaCTX-M genes and for 
strains containing blaAmpC genes. For blaCTX-M genes, 2 out of 8 donors, belonging to 
species C. freundii, generated transconjugants resistant to cefotaxime. For blaAmpC genes, 
3 out of 7 isolates identified as E. coli generated transconjugants. To confirm the identity 
of the transconjugant and the acquisition of the plasmid, BOX-PCR and detection of 
blaCTX-M and blaCMY genes was performed as described in Chapter II. 
For the resultant transconjugants, genomic characterization was performed in 
order to identify the genes previously found in the donor isolate. 
 Tables III.3 and III.4 summarize the genomic characterization of the AR genes 
present in the transconjugants based on the resistance genotype of the donors, for blaCTX-
M and blaCMY genes, respectively. 
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For conjugation experiments regarding isolates blaCTX-M-15+, blaTEM was present 
on ER13 and ER28 but it was only present in Tj13. blaSHV was present in ER28 and was 
transferred to the respective transconjugant. Class 1 integrase was detected in all donors 
and transconjugants; class 2 integrase was not detected in the transconjugant Tj28.  
Resistance to sulfonamides genes sul1 and sul2 were present in both donors but sul2 was 
only detected in Tj13 while sul1 gene was only present in Tj28. About fluoroquinolones 
resistance determinants, ER13 harbored aac(6’)-ib-cr gene and qnrB while ER28 
harbored qnrA. In Tj13 only one gene conferring resistance to fluoroquinolones is present, 
qnrB. In Tj28, qnrA is not present. In transconjugant Tj28, aac(6’)-ib gene is present. 
Isolate ER13 also harbored blaCMY gene, which was not detected in Tj13.  
 
Table III.3. Resistance genotypes of blaCTX-M-15 donors and transconjugants.  
Donor  Species bla gene Transconjugant 
Resistance Genotype 
Donor Transconjugant 
ER5 M. morganii
 
blaCTX-M-15 
- 
blaTEM, blaDHA, 
aac(6’)-ib, sul1, intI1  - 
ER13 C. freundii Tj13 blaTEM, blaCMY, qnrB, aac(6’)-ib-cr , 
sul1, sul2, intI1
 
blaTEM. qnrB, sul2, intI1 
ER18 M. morganii - blaTEM, blaDHA, aac(6’)-ib, sul1, intI1 - 
ER22 M. morganii - blaTEM, blaDHA, aac(6’)-ib, sul1, intI1 - 
ER23 M. morganii - blaTEM, blaDHA, aac(6’)-ib, sul1, intI1 - 
ER27 M. morganii - blaTEM, blaDHA, aac(6’)-ib, sul1, intI1 - 
ER28 C. freundii Tj28 blaTEM, blaSHV qnrA,aac(6’)-ib, 
sul1, sul2, intI1, intI2 
blaSHV, aac(6’)-ib, sul1, 
intI1 
ER30 M. morganii - blaTEM, blaDHA, aac(6’)-ib, sul1, intI1 - 
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For blaCMY+ isolates, blaTEM, class 1 integrase gene, aminoglycoside resistance 
gene aac(6’)-ib and genes conferring resistance to sulfonamides were detected. blaTEM 
was present in all 3 donors and respective transconjugants. aac(6’)-ib gene was present 
in all donors. intI1 and sul2 genes were both present in ER8 and ER33, this two isolates’ 
genotypes differed in the presence of sul1 gene – isolate ER8, was the only isolate 
harboring both sul1 and sul2. 
Aside from blaTEM and aac(6’)-ib gene, ER8 donor possessed sul1, sul2 and intI1 
genes, while in Tj8 only sul2 and intI1 genes were detected. ER26 also harbored 
resistance gene aac(6’)-ib and this gene was not detected in Tj26. Only blaTEM was 
detected in Tj26. aac(6’)-ib gene, sul2 and intI1 genes were present in ER33. From these 
3 genes, only sul2 was detected in Tj33. When present in the donor, neither sul1 or 
aac(6’)-ib genes were detected in the transconjugant.  
 
Table III.4. Resistance genotype of blaCMY donors and transconjugants.  
Donor Species bla gene Transconjugant 
Resistance Genotype 
Donor Transconjugant 
ER8 
E. coli 
blaCMY 
Tj8 
blaTEM, aac(6’)-ib, 
sul1, sul2, intI1  
blaTEM, sul2, intI1 
ER11 
E. coli - 
blaTEM, aac(6’)-ib, 
intI1 
- 
ER26 
E. coli Tj26 blaTEM, aac(6’)-ib blaTEM 
ER31 E. coli - blaTEM - 
ER33 
E. coli Tj33 
blaTEM, aac(6’)-ib, 
sul2, intI1 
blaTEM, sul2 
ER39 
E. coli - 
blaTEM, aac(6’)-ib, 
sul2, intI1 
- 
ER44 
E. aerogenes - 
blaTEM, aac(6’)-ib, 
sul2 
- 
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Plasmid DNA was extracted from donors and transconjugants to assess the 
plasmid DNA profiles of these isolates (Figure III.6).  
 
 
 
 
 
 
 
 
 
 
 
  
Figure III.6 – Results of Plasmid DNA Extraction. M – molecular marker; ER – isolates used as donors; Tj – 
transconjugants 
 
 
 
 
 
 
 
 
 
 
M    ERϴ     Tjϴ   ERϭϯ  Tjϭϯ  ERϮϲ  TjϮϲ  ERϮϴ  TjϮϴ  ERϯϯ  TJϯϯ  
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4. Replicon typing 
 Detection of IncA/C, IncB/O, IncF (FIA, FIB, FIC, FIIA, Frep subgroups), 
IncHI1, IncHI2, IncI1, IncK, IncX, IncL/M, IncN, IncP, IncT, IncW and IncY replicons 
was performed by PCR. Results are summarized in Table III.5. 
 The inc/rep PCR-based typing method was applied to all 46 isolates and 
transconjugants that resulted from the mating assay (n=5). Thus, cell suspensions were 
used for transconjugant and donor cells as well as for the remaining isolates. 
In a total of 46 isolates and 5 transconjugants, 13 isolates and 3 transconjugants gave a 
positive result for at least one Inc group. All 16 strains belong to E. coli species. 
 IncF, IncK, IncI1 and IncB/O specific sequences were detected among the 
isolates. IncF Frep subgroup was the most frequently identified, it was detected in 14 
isolates. Among these 14 isolates, 10 isolates harbored Frep subgroup and one or more 
replicon belonging to subgroup FIB, groups IncB/O, IncI1 and IncK. The remaining 
isolates harbored only Frep plasmids. FIB subgroup is present in 5 isolates, always 
associated with other replicon sequences. FIB subgroup is the only plasmid group that is 
present in one donor and absent in the respective transconjugant. 
IncK group was detected in ER8, ER26 and the respective transconjugants and 
always appears associated with either Frep subgroup or associated with both Frep and 
IncI1 replicons. IncI1 group appears in a total of 4 isolates and in 2 of them it is not 
associated with any other replicon sequences. In the other 2 groups, IncI1 appears 
associated with Frep subgroup and IncK and associated with IncF subgroups Frep and 
FIB. 
IncB/O is present only in ER33 and respective transconjugant. 
 Analysis of the presence of certain AR genes and the replicon typing, does not 
suggest a direct correlation between the presence of one gene and the presence of an Inc 
group, or vice-versa.  
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Table III.5. Results of the inc/rep PCR-based typing method. Only strains that gave a positive result in at least one PCR experiment were included in this table.  
Strain Multiplex 1 Multiplex 2 Multiplex 3 S implex Resistance Genotype 
B/O F/C A/C P T K W FIIA FIA FIB Y I1 X HI1 N HI2 L/M Frep 
ER6 - - - - - - - - - - - - - - - - - + blaTEM, blaCTX-M, aac(6’)-ib, sul1, intI1 
ER8 
- - - - - + - - - - - + - - - - - + blaTEM, blaCMY, aac(6’)-ib, sul1, sul2, intI1 
Tj8 - - - - - + - - - - - + - - - - - + blaTEM, blaCMY, sul2, intI1 
ER11 
- - - - - - - - - - - + - - - - - - blaTEM, blaCMY, aac(6’)-ib, intI1 
ER15 - - - - - - - - - - - - - - - - - + blaTEM, aac(6’)-ib, sul1, intI1  
ER19 
- - - - - - - - - - - - - - - - - + blaTEM, blaDHA, aac(6’)-ib, intI1 
ER26 - - - - - + - - - - - - - - - - - + blaTEM, blaCMY, aac(6’)-ib 
Tj26 
- - - - - + - - - - - - - - - - - + blaTEM, blaCMY 
ER31 - - - - - - - - - + - - - - - - - + blaTEM, blaCMY 
ER33 + - - - - - - - - + - - - - - - - + blaTEM, blaCMY, aac(6’)-ib, sul2, intI1 
Tj33 + - - - - - - - - - - - - - - - - + blaTEM, blaCMY, sul2 
ER35 
- - - - - - - - - + - - - - - - - + blaTEM, blaCTX-M-15, aac(6’)-ib, intI1 
ER36 
- - - - - - - - - + - - - - - - - + blaTEM, blaCTX-M-15, aac(6’)-ib 
ER40 
- - - - - - - - - - - - - - - - - + blaTEM, aac(6’)-ib, sul2 
ER41 
- - - - - - - - - + - + - - - - - + blaTEM, blaCMY, aac(6’)-ib 
ER43 - - - - - - - - - - - + - - - - - - blaTEM, blaCMY, aac(6’)-ib 
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IV. DISCUSSION 
This study aimed to contribute for the development of effective strategies to 
reduce resistance prevalence in clinical settings by characterizing the genetic basis of the 
resistance phenotypes associated with infectious bacteria in Hospital Infante D. Pedro, 
Centro Hospitalar do Baixo Vouga, E.P.E., as well as the mobility potential of the 
identified genes. Since antibiotic resistance is a worldwide problem with serious 
consequences in the clinical setting, there is a need to define strategies that can be applied 
in this environment to contribute for the future mitigation of antibiotic resistance 
dissemination. Controlling antibiotic resistance in healthcare systems might increase 
successful antimicrobial therapy rates and, as consequence, reduce mortality and 
morbidity rates as well as the treatment costs as the hospital stay would decrease.  
 
To define effective control strategies it is imperative to characterize the bacteria 
that occur in the study environment. Know not only the provenance of the isolates or 
identify the species but also the genetic relatedness among them by performing a typing 
analysis. Molecular typing allows the establishment of epidemiologic relationships 
among isolates giving evidence for clonal or horizontal dissemination. While clonal 
isolates share the same DNA fingerprint, polyclonal infections are characterized by 
unrelated isolates which have different DNA profiles. If isolates with the same DNA 
profile are collected from different patients, it implies a transmission among patients or a 
common contamination source and requires a strategy aiming this spread among patients 
or wards. Unrelated isolates are commonly found in a community-acquired scenario. 
However, they can be found in a nosocomial scenario and this is probably due to the 
selective pressure that is imposed by the antibiotics in this settings (Paterson & Bonomo, 
2005).  
The isolates used in this work were collected from inpatients, which represented 
the nosocomial infections, and outpatients (patients attending the emergency room) which 
represented the community-acquired infections since the community environment is also 
a reservoir of antibiotic resistance (Roxo, 2015). 
Molecular typing experiments allowed to assess the genetic diversity between the 
46 isolates characterized in this study and the combined use of three PCR typing methods 
(ERIC-, BOX and REP-PCR) allowed a better discrimination of the isolates.  
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Analyzing the dendrogram, it was possible to observe a good distinction between 
species, with a few exceptions, which increases the confidence in Vitek2®’s results. 
Within the species clusters there was a high intra-species variability, suggesting that the 
dissemination of ESBL-producers and blaAmpC-carriers was not clonally related. 
Furthermore, species clustering does not correlate with the isolates origin (clinic or 
community). This variability is probably due to the diverse origins of the isolates, both 
coming from the community and the hospital environment. 
 
The presence of clinically relevant resistance genes was searched by PCR. These 
genes encoded resistance to β-lactams, fluoroquinolones and sulfonamides.  
Regarding β-lactams, blaSHV, blaTEM, blaCTX-M and blaAmpC genes were searched 
in the context of explaining a resistance phenotype to penicillins and broad-spectrum 
cephalosporins. Resistance to broad-spectrum cephalosporins in Enterobacteriaceae can 
be due to: i) production of ESBLs, ii) overexpression of chromosomal blaAmpC genes, and 
iii) plasmid-encoded blaAmpC genes (Conen et al., 2015; Pfeifer et al., 2010). 
blaCTX-M gene was found in 18 of 46 isolates (39.1% prevalence). 17 isolates 
displayed a resistance phenotype against broad-spectrum cephalosporins and harbored the 
CTX-M-15 variant. Previous works demonstrated that this variant is frequently found in 
clinical environments and associated with Enterobacteriaceae isolates (Conen et al., 
2015; Dedeic-Ljubovic et al., 2009; Eckert et al., 2004). blaCTX-M-15 variant is also 
frequently associated with insertion sequence ISEcp1 located upstream the gene as well 
as orf477 downstream. It is important to evaluate the genomic context to assess the 
possible mobilization of the bla genes. It was possible to observe that the array ISEcp1-
blaCTX-M-15-orf477 is a success structure in this clinical setting, as seen in previous studies 
(Eckert et al., 2006; Salladin et al., 2002).  
Insertion sequences, namely ISEcp1, serve as vehicle for the dissemination of 
these genes (Eckert et al., 2006). Aside from ISEcp1, other insertion sequences have been 
detected surrounding this bla gene, namely, IS26 (Cullik et al., 2010). This insertion 
sequence was screened in isolate ER6 since this was the only isolate harboring a blaCTX-
M gene for which ISEcp1 was not detected upstream of the gene. Sequence analysis of the 
PCR amplicon was not successful so the variant and the upstream genomic context 
remained unknown. ER6 is also the only isolate that was susceptible to broad-spectrum 
cephalosporins. This is an uncommon situation since CTX-M enzymes have high 
hydrolytic activity against cefotaxime, hence the name CTX-M – active on CefoTaXime, 
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isolated on Munich (Bush & Fisher, 2011). Based on the fact that the PCR amplicon for 
IS26 gave a positive band with similar size to the positive control, one hypothet ica l 
explanation for the lack of expression of this CTX-M could be that the IS26 is interrupting 
the coding sequence of the blaCTX-M gene. However, to best of our knowledge, there are 
no reports regarding the interruptions of blaCTX-M genes by IS26 that support this 
hypothesis. There is one study describing the interruption of a coding sequence, encoding 
a porin OmpK36, by IS26 (Mena et al., 2006).  
Variants blaCMY, blaDHA and blaEBC of blaAmpC genes were found, collectively, in 
65.2% of the isolates. According to previous studies, the variant blaCMY descended from 
a blaAmpC located in the chromosome of C. freundii, the variant blaDHA derived from M. 
morganii blacAmpC gene and blaEBC (coding ACT-1 and MIR-1 β-lactamases) is descended 
from a blacAmpC gene found in E. cloacae (Barlow & Hall, 2002). Based on this 
information, blaDHA genes found in M. morganii isolates were considered to be intrins ic, 
and the same is valid for blaCMY found in C. freundii and blaEBC found in E. cloacae. In 
opposite, blaDHA genes found in E. coli and blaCMY genes found in E. coli, E. aerogenes 
and E. cloacae, were considered to be acquired. In accordance to other studies, in this 
work cAmpCs were more prevalent than pAmpC (Conen et al., 2015). 
Chromosomal AmpC β-lactamases can either be over-produced through 
mutations in the promotor region which derepresses the AmpC production or induced by 
the exposition to β-lactams (Conen et al., 2015). Enterobacteriaceae isolates harboring 
cAmpC can initially be susceptible to cefotaxime, which is the case of isolates ER14 and 
ER17, but, in a clinical situation, the administration of 3rd generation cephalosporins will 
result in selection of mutants and consequently recurrence of the infection (Paterson, 
2006). In a context of resistance dissemination, pAmpC are more relevant than cAmpC 
since the identification of a species that harbors these β-lactamases is enough to indicate 
their presence and avoid the administration of broad-spectrum cephalosporins (Thomson, 
2010). Also, pAmpC enzymes are usually associated with penicillinases or other 
cephalosporinases (Jacoby, 2009) and that was showed in this study, when present, a 
pAmpC was always associated with another β-lactamase, either TEM, SHV or CTX-M.  
The variant of the blaCMY present in an acquired scenario was determined by 
sequence analysis but it was only possible to identify the variant as part of the CMY-2 
group. Within this group, the variant present in the 11 isolates can either be CMY-2 or 
CMY-22. Considering the fact that CMY-2 is the most prevalent and with the widest 
geographic distribution (Philippon et al., 2002) the genomic context was inspected for 
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insertion sequence ISEcp1since it is associated with the mobilization of acquired AmpCs 
(Verdet et al., 2009). For 6 isolates, ISEcp1 was present suggesting a role in the 
mobilization of this gene. IS5 has also been reported associated with blaCMY-2 (Verdet et 
al., 2009) gene but was not present in none of the isolates. One possible solution for 
accessing the CMY variant is to amplify the blaCMY gene using a reverse primer designed 
to ligate to the blc gene which is frequently located downstream the blaCMY-2 variant 
(Ahmed & Shimamoto, 2008; Mata & Navarro, 2012).  
Some isolates displayed resistance to broad-spectrum cephalosporins but blaCTX-
M and blaAmpC (either chromosomal or plasmidic) genes were absent. Therefore, blaTEM 
and blaSHV genes were also screened since TEM- and SHV-type ESBLs could explain 
these phenotypes. blaTEM was the most prevalent gene in the collection (97.8%), detected 
in all isolates except isolate ER45, and blaSHV was the least frequent (6.5%), present in 
isolates ER25, ER28 e ER29. Despite the presence of these genes, the variant was not 
assessed, therefore, it was not possible to distinguish between ESBLs and TEM-1 and 
SHV-1 families. While blaSHV-1, blaTEM-1 and blaTEM-2 genes encode resistance to 
penicillins and early cephalosporins, TEM- and SHV-type ESBL also confer resistance 
to broad-spectrum cephalosporins. In some cases, the presence of blaSHV or blaTEM 
suggests the presence of TEM-1 and SHV-1 penicillinases, since the isolate only displays 
resistance to penicillins, while in others, suggests the presence of an ESBL type based on 
the broad-spectrum cephalosporins resistance phenotype (Bush, 2010; Bush & Jacoby, 
2010). In this case, the knowledge of the gene variant would be determinant to distinguish 
the β-lactamase present and make a comparison between the resistance phenotype and the 
genotype. Both TEM- and SHV-type ESBL and TEM-1 and SHV-1 families have been 
detected in Enterobacteriaceae (Pfeifer et al., 2010). 
It is worth to highlight that ER45 does not harbor any bla gene tested and displays 
resistance to 3rd generation cephalosporins. One possible explanation for this situation, is 
that isolate ER45 harbors other ESBL types like VEB or PER, which are less common 
but were found in Enterobacteriaceae, and could explain the resistance phenotype to 
broad-spectrum cephalosporins and the susceptibility to carbapenems (Paterson & 
Bonomo, 2005; Weldhagen et al, 2003). 
In a clinical scenario, the distinction between pAmpC producers and ESBL 
producers is imperative, since organisms producing high levels of pAmpCs can be 
misclassified as ESBL producers. Another problematic situation occurs when the 
presence of a pAmpC masks the effect of the ESBL and the isolate is considered ESBL-
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negative (Munier et al., 2010; Robberts et al., 2009). This results in inappropriate therapy. 
Until the moment, there is no time-effective method available that allows a reliable 
identification (Conen et al., 2015).  
Plasmid mediated resistance to fluoroquinolones can be due to three mechanisms. 
The first mechanism is mediated by qnr genes, which code for proteins that protect DNA 
gyrase and topoisomerase IV from quinolone action. The second, involves a variant of 
the aminoglycoside acetyltransferase, aac(6’)-ib-cr, that has the ability to modify and 
reduce the activity of quinolones. Finally, the last mechanism involves efflux of the 
antibiotic coded by pumps’ genes qepA. These mechanisms only provide low-level 
resistance but facilitate the emergence of high-level resistance in the presence of 
therapeutic levels of fluoroquinolones (Jacoby et al., 2014; Robicsek et al., 2006). In this 
context, variants qnrA, qnrB and qnrS of qnr genes and aac(6’)-ib-cr were searched.  
The qnrA and qnrB genes were found only in C. freundii isolates. According to 
other studies, qnrB is the most frequent variant found in clinical Enterobacteriaceae 
(Jacoby et al., 2011)  and Citrobacter spp. is considered as the origin of qnrB allele 
(Ribeiro et al., 2015). qnrA is also found in C. freundii isolated from clinica l 
Enterobacteriaceae (Cambau et al., 2006). 
The screening of aac(6’)-ib-cr gene was performed with the same primers used 
for aac(6’)-ib. Without sequencing, it is not possible to distinguish between these two 
variants. Only one amplicon was sequenced, corresponding to isolate ER13 and it was 
confirmed to be the aac(6’)-ib-cr variant. This isolate harbors two genetic determinants 
conferring low-level resistance to fluoroquinolones and displays resistance to CIP and 
LVX. aac(6’)-ib gene is only absent in two isolates, ER31 and ER42, both of them are 
susceptible to LVX and CIP and are also susceptible to the aminoglycosides tested, 
namely amikacin, gentamicin and tobramycin. For the remaining isolates, among the ones 
that tested positive for the presence of aac(6’)-ib, there are isolates displaying resistance 
to fluoroquinolones and aminoglycosides and isolates that are susceptible to both classes. 
Moreover, there are isolates that harbor the gene and are susceptible to aminoglycos ides 
and resistant to fluoroquinolones. Sequencing the amplicon would allow to assign the 
gene variant to a certain antibiotic class and understand which phenotype it confers.  
Sulfamethoxazole is the most commonly used sulfonamide and is used in 
combination with trimethoprim forming sulfamethoxazole/trimethoprim (or 
cotrimoxazol). Since some isolates displayed resistance to cotrimoxazol, sul1 and sul2 
were screened in all isolates. Both genes have been reported in clinical isolates of 
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Enterobacteriaceae members, some of which were ESBL-producing isolates (Antunes et 
al., 2005; Frank et al., 2007; Singha et al., 2015). Isolates ER3 and ER19 displayed 
resistance to cotrimoxazol, however, neither sul1 nor sul2 genes were present. In these 
cases, the presence of sul3 gene might explain the phenotype (Perreten & Boerlin, 2003). 
This variant has been found in Enterobacteriaceae clinical isolates (Grape et al., 2003). 
However, resistance can arise from other mechanisms that were not studied in this work. 
ESBL-producing organisms frequently display co-resistance to other antibiot ic 
classes, namely, aminoglycosides, tetracyclines, sulfonamides and fluoroquinolones. 
This was observed in this study and it is probably due to horizontal gene transfer due to 
dissemination agents (Cantón & Coque, 2006). 
 
This leads to the other main goal of this work that was to detect the potential 
mobility of the resistance genes screened. In this sense, detection and characterization of 
mobile genetic elements, like insertion sequences, integrons and plasmids, was 
performed.  
Detection of insertions sequences was performed when the genomic context of 
blaCTX-M and blaCMY was evaluated and only ISEcp1 was found. In Enterobacteriaceae 
bacteria, the presence of blaCTX-M genes associated to this insertion sequence were 
suggested to be embedded in transposon elements, thus enhancing the occurrence of 
transposable events (Poirel et al., 2003). Besides ISEcp1, other insertions sequences, 
namely IS26 and ISCR, have been associated with bla genes (Cantón & Coque, 2006). 
The ISCR element has been associated to blaCTX-M and blaCMY as well as 
fluoroquinolones’ resistance gene qnrA. Moreover, ISCR1 was reported in a complex 
structure involving class 1 integrons (Toleman et. al, 2006b).  
A class 1 integron is composed of a variable region flanked by two conserved 
segments, 5’CS and 3’CS. On the 5’ terminal, there are three key elements: an integrase 
gene (intI1), a recombination site (attI) and a promoter (Pc). The 3’CS region englobes 
the qacEΔ1 gene, coding resistance to quaternary ammonium compounds and the sul1 
gene, which confers resistance to sulfonamides (Domingues et al., 2012). Integrons, by 
themselves, are not considered mobile elements because they lack of self-mobility 
functions, however they are able to integrate gene cassettes so they have a roll in 
multidrug phenotype (Boucher et al., 2007). In this sense, class 1 and class 2 integrase 
genes were searched in all isolates. When present, the variable region was also 
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characterized, since it can harbor antibiotic resistance genes. Class 1 integrons were 
highly prevalent among the isolates (73.9%) while only one class 2 integron was found 
in the collection (2.2%). Comparing to a recent study in Enterobacteriaceae clinica l 
isolates, the number of class 1 integrons was higher while the number of class 2 integrons 
was similar (Malek et al., 2015). 
The gene cassettes found consisted in 7 different arrays. The most frequent array 
contained dfrA15 gene cassette, which confers resistance to trimethoprim. Other gene 
cassettes were detected, among them: aadA1, aadA2, aadA5 and aadB (resistance to 
aminoglycosides), dfrA1, dfrA12 and dfrA17 (resistance to trimethoprim), catB3 
(chloramphenicol) and sat2 (streptothricin). In some isolates, the presence of these gene 
cassettes explained a multidrug resistance phenotype. These arrays were previously 
reported according to the information available at the INTEGRALL Database (availab le 
at: http://integrall.bio.ua.pt/).  
Based on the fact that sul1 gene is a part of the structure of the integron, it was 
expected that all the isolates harboring intI1 gene, also harbored sul1 gene. But, that was 
not the case. In 13 isolates, the intI1 gene was present and sul1 was absent. There are 
reports of integrons lacking the 3’CS region. One of the possible explanations for this, is 
the substitution of the sul1 gene for the sul3 gene in the 3’CS region. If these isolates 
tested positive for the presence of sul3, the variable region could be tested using a forward 
primer for the intI1 gene and a reverse primer for the sul3 region (Grape et al., 2003; 
Toleman et al., 2006b).  
blaCTX-M genes have also been associated to epidemic plasmids. These plasmids 
frequently harbor other antibiotic resistance genes besides blaCTX-M genes, located in the 
same plasmid, conferring resistance to various antibiotic classes (Cantón & Coque, 2006). 
Since these plasmids can be transferred among isolates, their mobility was evaluated by 
performing conjugation experiments. To attribute the identified plasmid to certain Inc 
groups, after the mating assays, replicon typing was performed.  
The mating assays were performed for blaCTX-M and blaCMY genes. For blaCTX-M 
genes only 2 donor strains among the 8 blaCTX-M+ isolates were able to pass the phenotype 
to the recipient cells. And for blaCMY+, the same was observed for 3 out of 7 donors. The 
number of transconjugants obtained is similar to the number obtained in other studies 
using E. coli J53 AzideR as recipient cell (Tacão et al., 2014). This recipient was also 
tested, but the donors were able to grow on culture media supplemented with azide 
maximum concentration tested for the growth of recipient cell, so it was not possible to 
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use another recipient strain. The recipient strain used was E. coli CV601 RIFR and it is 
not frequently described in conjugation experiments. Although, in previous studies, using 
this recipient strain and Enterobacteriaceae donors, the conjugation success was higher 
than the one obtained in this study (Moura et al., 2014; Smalla et al., 2000).  
The identification of plasmid replicon types is important in the plasmid 
epidemiological surveillance because some Inc groups are typically associated with the 
carriage of certain resistance genes. In Enterobacteriaceae the major plasmid families 
present are: IncA/C, IncB/O, IncF (FIA, FIB, FIC, FIIA, Frep subgroups), IncHI1, 
IncHI2, IncI1, IncK, IncX, IncL/M, IncN, IncP, IncT, IncW and IncY (Carattoli, 2009). 
All these families were screened but only IncF, IncK, IncI1 and IncB/O replicons were 
found among the isolates and transconjugants for blaCMY gene.  
Plasmid DNA extraction results revealed in gel a multiband pattern for the blaCMY+ 
isolates, namely, Tj8, ER26, ER33 and Tj33 (Figure III.6). These isolates were also 
positive for more than one Inc group. These results suggest the presence of mult ip le 
plasmids belonging to several Inc groups. However, it is not possible to affirm this 
considering the fact that some plasmids can harbor more than one type of replicon in order 
to have a broader host range. The presence of multireplicon plasmids cannot be discarded 
in this situation (Boyd et al., 1996; Osborn et al., 2000).   
 blaCTX-M-15 is associated with plasmids belonging to the IncF group, more 
frequently in subgroups FIIA, FIA and FIB, in isolates originated from humans (Carattoli, 
2009). This was observed in the 2 blaCTX-M-15+ isolates that were positive for at least one 
replicon, both of them harbored FIB replicons, as well as Frep subgroup sequences . 
Moreover, the structure ISEcp1-blaCTX-M-15 is found in the IncF group in hospital isolates 
and it is frequently associated with blaTEM-1 (Boyd et al., 2004). In this study, isolates 
blaCTX-M+ that harbored IncF plasmids, were also positive for blaTEM genes, however, the 
gene variant was not confirmed to be blaTEM-1. IncF plasmids originated from human 
samples are also associated with blaCMY and blaDHA as well as aminoglycosides and 
fluoroquinolones resistance genes (Carattoli, 2009), which is in accordance with the 
results found in this study. IncI1 group appears associated with blaTEM and blaCMY genes 
(Carattoli, 2009; Hordijk et al., 2013a) which is also in accordance with the results 
obtained.  
 Plasmids belonging to IncK group are highly related to the ones belonging to 
group B/O (Praszkier et al., 1991). Both of these replicons have been reported in 
Enterobacteriaceae, although, these replicon types are typically associated with blaCTX-
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M-14 and blaCTX-M-9 gene variants and this was not verified in this study (Carattoli, 2009; 
Lyimo et al., 2016). Recently, IncK plasmids were found associated with blaCMY-2 in 
animal (Hordijk et al., 2013b) and human samples (Hansen et al., 2016; Seiffert et al., 
2017). As well as IncB/O plasmids (Seiffert et al., 2017).  
The isolates studied in this work were characterized in terms of genetic 
relatedness, genes conferring resistance phenotype to several antibiotic classes and 
potential mobility of the resistance genes found. Except isolate ER45, all isolates harbor 
at least one ESBL or an AmpC β-lactamase. As said before, ESBL-producing organisms 
frequently harbor resistance to other antibiotic classes and this is probably due to the co-
occurrence of genetic determinants in the same mobile genetic elements. Results 
regarding mating experiments and the characterization of the variable regions of the class 
1 and 2 integrons supported this hypothesis. Our results confirm that mobile genetic 
elements play a major role in the dissemination of resistance determinants in the analyzed 
hospital, contributing to the spread of successful resistance arrays. Future strategies to 
control the dissemination of resistance should be designed taking this information into 
account. 
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V. CONCLUSION 
Enterobacteriaceae isolates displaying resistance to broad-spectrum 
cephalosporins or harboring ESBLs and/or AmpC enzymes are relevant in the clinica l 
setting. This family of antibiotics is the main choice to treat infections caused by Gram-
negative bacteria and is considered critically relevant in human medicine. Moreover, the 
presence of ESBLs is frequently associated with genes conferring resistance to other 
antibiotic classes which diminishes the therapeutic options.  
The fact that multidrug resistant isolates are becoming more prevalent in the 
clinical settings, shows the importance of evaluating the provenance of the isolates found 
in the hospital, since the clinical setting is a “hotspot” of different resistance determinants. 
This, associated with the ease by which these resistance determinants can spread among 
bacteria, thanks to horizontal gene transfer mechanisms, makes it imperative to define 
strategies that reduce this dissemination among clinical wards. 
This study provided a general sight of the resistance genotypes found in isolates 
recovered from patients that were treated in Hospital Infante D. Pedro, Centro Hospitalar 
do Baixo Vouga, E.P.E., during a one year period, which complements the phenotypic 
study done before.  
It was possible to conclude that resistance to 3rd generation cephalosporins in this 
hospital is predominantly associated to acquired mechanisms. Moreover, the 
dissemination of these resistance determinants seems to be related with the transference 
of mobile genetic elements rather than with clonal spread.  
However, it was not possible to point a certain resistance genotype to one specific 
dissemination vehicle. The results obtained in this study suggest that the resistance 
phenotype present in this particular clinical setting results from the horizonta l 
transference of more than one mobile genetic element. Further studies need to be 
conducted to characterize these elements with more detail. 
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In summary, some final considerations concerning this study include: 
• High intra-species diversity suggests a non-clonal spreading among wards; 
• ESBL-encoding blaCTX-M-15 was frequently detected, in accordance with previous 
studies; 
• blaCTX-M-15 context includes insertion sequences typically associated with this 
gene; 
• Acquired AmpC-encoding genes were also frequent, particularly among E. coli 
isolates; 
• The majority of blaCMY gene in an acquired scenario is associated with an insertion 
sequence frequently found linked to this gene;  
• qnr genes were only found in Citrobacter freundii isolates, in accordance with 
previous studies;  
• Class 1 integrons were highly prevalent, in some cases explaining a multi-drug 
phenotype; 
• Plasmids belonging to IncF, IncI1 and IncB/O groups were found in these clinica l 
isolates harboring bla genes, which is in accordance with previous studies. 
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VII. SUPPLEMENTAL MATERIAL 
Presented below are the amino acid sequences of AmpC β-lactamases belonging 
to CMY-2 group available in CARD database. These sequences along with the sequences 
from ER isolates were used to perform the multiple sequence alignment with 
ClustalOmega. 
>gi| CMY-2 [Klebsiella pneumoniae] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ 
>gi|CMY-4 [Proteus mirabilis] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARG YREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-5 [Klebsiella oxytoca] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKFSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ 
>gi|CMY-6 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYALGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-7 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGELAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
 
 
 
 
84 
 
>gi|CMY-12 [Proteus mirabilis] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYSNSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKNYPNPVRVEAAWRILEKLQ  
>gi|CMY-13 [Escherichia coli] 
MMKKSLCCALLLTASFSTFASAKTEQQIADIVNRTITPLMQEQAIPGMAVAIIYQGKPYYFTWGKADIANNHPVTQQTL
FELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGISLLHLATYTAGGLPLQIPDDVTDKAALLRFYQNW
QPQWAPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPG
QLDAEAYGVKSNVTDMARWVQVNMDASRVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-14 [Proteus mirabilis] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEINPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ 
>gi|CMY-15 [Proteus mirabilis] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKNYPNPVRVEAAWRILEKLQ  
>gi|CMY-16 [Proteus mirabilis] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYSNSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-18 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQI PDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGN
GSDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-20 [Escherichia coli] 
MKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADIANNHPVTQQTLF
ELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGISLLHLATYTAGGLPLQIPDDVTDKAALLHFYQNWQ
PQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSPGQ
LDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGSDN
KVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
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>gi|CMY-21 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGELAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GKLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGS TGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ 
>gi|CMY-22 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAYWRILEKLQ  
>gi|CMY-23 [Salmonella enterica subsp. enterica serovar Senftenberg] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAGAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-24 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVYVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ 
>gi|CMY-25 [Klebsiella pneumoniae] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVTDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-26 [Klebsiella oxytoca] 
MMKKSLCCALLLTASFSTFASAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKTYYFTWGKADIANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQDISLLHLATYTAGGLPLQIPDDVTDKTALLHFYQN
WQPQWAPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQSEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSNVTDMARWVQVNMDASRVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIING
SDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-27 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYACGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ 
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>gi|CMY-29 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQFPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGELAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-30 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHGS
PGQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIING
SDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI VMLANKSYPNPVRVEAAWRILEKLQ 
>gi|CMY-31 [Klebsiella pneumoniae] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GRLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-33 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-36 [Klebsiella pneumoniae] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDCIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGG LPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPENEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-38 [Proteus mirabilis] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSP
GQLNAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKNYPNPVRVEAAWRILEKLQ  
>gi|CMY-40 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGISLLHLATYTAGGLPLQIPDDVTDKAALLRFYQN
WQPQWTPGAKRLYANSSIGLFGTLAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQSEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMAHWVQANMDASHVQEKTLQQGIELAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHK TGYTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ 
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>gi|CMY-42 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHSSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-44 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVAPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ 
>gi|CMY-45 [Proteus mirabilis] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLKIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYSNSSIGLFGALAVKPSGMSYEEAMTRRVLQPLK LAHTWITVPQNEQKDYARGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTVGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-49 [Citrobacter freundii] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQ AIPGMAVAIIYQGKPYYFTWGKADIANNHPVTQQTL
FELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGISLLHLATYTAGGLPLQIPDDVTDKAALLRFYQNW
QPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVTPG
QLDAEAYGVKSNVTDMARWIQVNMDASRVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLK ADSIINGSD
SKVALAALHTVEVNPPAPAVKASWVHKTGSTGGFGSYVAFIPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-53 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGICLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIELAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPARVEAAWRILEKLQ  
>gi|CMY-59 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHASP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|CMY-99 [Proteus mirabilis] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYSNSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYARGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPATAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
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>gi|AGC54798.1|CMY-94 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVASAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ 
>gi|AGC54799.1|CMY-95 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHASP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVASAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|AGZ20169.1|CMY-108 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGISLLHLATYTAGGLPLQIPDDVTDKAALLRFYQN
WQPQWAPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQSEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQVNMDASRVQ EKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWHILEKLQ  
>gi|AHW47897.1|CMY-111 [Serratia marcescens] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDVEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ 
>gi|CAA55007.1|LAT-1 [Klebsiella pneumoniae] 
MMKKSLCSALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDCIARGEIKLSDPVTKYWPELTGKKWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GRLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPVRVEAAWRILEKLQ  
>gi|BAC76072.1|CFE-1 [Escherichia coli] 
MMKKSICCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAIIYQGKPYYFTWGKADIANNRPVTQQTL
FELGSVSKTFNGVLGGDAIARGEIKLSDPVTQYWPELTGKQWQGISLLHLATYTAGGLPLQVPDDVTDKAALLRFYQN
WQPQWAPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTTRVLQPLKLAHTWITVPQSEQKDYALGYREGKPVHVSPG
QLDAEAYGVKSSVVDMTRWVQANMDASQVQEKTLQQGIKLAQSRYWRIGDMYQGLGWEMLNWPVKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLANKSYPNPARVEAAWRILEKLQ 
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>ER8 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI  
>ER11 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIA 
>ER26 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI  
>ER31 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI  
>ER33 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKN 
>ER39 [Escherichia coli] 
MMKKSLCCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKADI ANNHPVTQQT
LFELGSVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLHFYQN
WQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAWGYREGKPVHVSP
GQLDAEAYGVKSSVIDMARWVQANMDASHVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNWPLKADSIINGS
DSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKN 
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Table S.1 summarizes all the information regarding antibiotic susceptibility tests 
given by Vitek2® automated system.  
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Table S.1. Results regarding antibiotic susceptibility testing given by Vitek2® Automated System. 
Isolate Species  
MICs  of each antibiotic 
AMK AMC AMP CEF CTX CAZ CXMa CMXs  CIP SXT ERT GEN IPM LVX MEM NIT TZP TOB 
ER1 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - S ;чϭͿ S R (16) R (16) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ I ;чϰͿ S ;чϭͿ 
ER2 M. morganii I (8) R ;шϯϮͿ R ;шϯϮͿ R ;шϲϰͿ R ;шϲϰͿ R (2) R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ R ;шϭϲͿ - R ;шϴͿ S (0.5) - I ;чϰͿ R ;шϭϲͿ 
ER3 E. coli R R ;шϯϮͿ R R R R - - R R S R S R S R R R 
ER4 M. morganii S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (8) R (4) R ;шϲϰͿ R ;шϲϰͿ R (2) R ;шϯϮϬͿ S ;чϬ.ϱͿ R ;шϭϲͿ - R (2) S ;чϬ.ϮϱͿ R (128) I ;чϰͿ R (2) 
ER5 M. morganii R (8) R ;шϯϮͿ R ;шϯϮͿ - R ;шϲϰͿ R (8) R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ R ;шϭϲͿ - R ;шϴͿ S ;чϬ.ϮϱͿ R (128) I (8) R ;шϭϲͿ 
ER6 E. coli S ;чϮͿ R (16) R ;шϯϮͿ - S ;чϭͿ S ;чϭͿ R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮͿ S ;чϬ.ϱͿ S ;чϭͿ S R ;шϴͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ S (8) S ;чϭͿ 
ER7 M. morganii I (8) R (шϯϮͿ R ;шϯϮͿ - R (8) R (8) R ;шϲϰͿ R ;шϲϰͿ R (2) R ;шϯϮϬͿ S ;чϬ.ϱͿ R ;шϭϲͿ - R (2) S (0.5) R (128) I ;чϰͿ R (8) 
ER8 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (4) R (4) R (16) R (16) R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S R ;шϴͿ S ;чϬ.ϮϱͿ S (64) I ;чϰͿ S ;чϭͿ 
ER9 E. cloacae S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - S ;чϭͿ S ;чϭͿ R (16) R (16) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ I (64) S ;чϰͿ S ;чϭͿ 
ER10 E. aerogenes S ;чϮͿ R ;шϯϮͿ R (8) - S ;чϭͿ S ;чϭͿ S (4) S (4) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ I (64) S ;чϰͿ S ;чϭͿ 
ER11 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (4) R (16) R (16) R (16) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ I (8) S ;чϭͿ 
ER12 S. marcescens Unknown 
ER13 C. freundii S ;чϮͿ R (8) R ;шϯϮͿ - R ;шϲϰͿ R (8) R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S R ;шϴͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ S ;чϰͿ S ;чϭͿ 
ER14 M. morganii S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - S ;чϭͿ S ;чϭͿ R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ S ;чϮϬͿ S ;чϬ.ϱͿ R (8) - R ;шϴͿ S ;чϬ.ϮϱͿ R (128) S ;чϰͿ R (8) 
ER15 E. coli S (4) R ;шϯϮͿ R ;шϯϮͿ - R (2) R (4) R (16) R (16) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ I (8) S ;чϭͿ 
ER16 E. aerogenes S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (16) R ;шϲϰͿ R ;шϲϰͿ R ;шϲϰͿ S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ R (128) R ;шϭϮϴͿ S ;чϭͿ 
ER17 E. cloacae S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - S ;чϭͿ S ;ч1) R (4) S (4) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ S (32) S ;чϰͿ S ;чϭͿ 
ER18 M. morganii I (16) R ;шϯϮͿ R ;шϯϮͿ - R ;шϲϰͿ R (4) R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ R ;шϭϲͿ - R ;шϴͿ S ;чϬ.ϮϱͿ R (128) I ;чϰͿ R ;шϭϲͿ 
ER19 E. coli S ;чϮͿ R (16) R ;шϯϮͿ - S ;чϭͿ S ;чϭͿ R (16) R (16) R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S R ;шϴͿ S ;чϬ.ϮϱͿ R (256) S (8) S ;чϭͿ 
ER20 M. morganii Unknown 
ER21 M. morganii S (4) R ;шϯϮͿ R ;шϯϮͿ - R (32) R (8) R ;шϲϰͿ R ;шϲϰͿ R (2) R ;шϯϮϬͿ S ;чϬ.ϱͿ R ;шϭϲͿ - R (2) S (0.5) R (128) I ;чϰͿ R (8) 
ER22 M. morganii Unknown 
ER23 M. morganii S (4) R ;шϯϮͿ R ;шϯϮͿ - R (32) R ;шϲϰͿ R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ R (8) - R ;шϴͿ S ;чϬ.ϮϱͿ R (128) I ;чϰͿ R (8) 
ER24 M. morganii I (8) R ;шϯϮͿ R ;шϯϮͿ - R (4) R (8) R ;шϲϰͿ R ;шϲϰͿ R (2) R ;шϯϮϬͿ S ;чϬ.ϱ) R ;шϭϲͿ - R (2) S (0.5) R (128) I (8) R (8) 
ER25 E. aerogenes Unknown 
ER26 E. coli - R ;шϯϮͿ R ;шϯϮͿ - R (2) R (4) R (16) R (16) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ I ;чϰͿ S ;чϭͿ 
ER27 M. morganii I (16) R ;шϯϮͿ R ;шϯϮͿ - R ;шϲϰͿ R (2) R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ R ;шϭϲͿ - R ;шϴͿ S ;чϬ.ϮϱͿ R (128) I ;чϰͿ R ;шϭϲͿ 
ER28 C. freundii I (16) R ;шϯϮͿ R ;шϯϮͿ - R (8) R ;шϲϰͿ R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ R ;шϭϲͿ S R ;шϴͿ S ;чϬ.ϮϱͿ R (256) R (32) R ;шϭϲͿ 
ER29 M. morganii S (4) R ;шϯϮͿ R ;шϯϮͿ - R (16) R (16) R ;шϲϰͿ R ;шϲϰͿ R (2) S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ - R (4) S (0.5) R (256) I ;чϰͿ S ;чϭ) 
ER30 M. morganii I (16) R ;шϯϮͿ R ;шϯϮͿ - R ;шϲϰͿ R (2) R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ R ;шϭϲͿ - R ;шϴͿ S ;чϬ.ϮϱͿ R (128) I ;чϰͿ R ;шϭϲͿ 
ER31 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (2) R (4) R (16) R (16) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S (0.5) S ;чϬ.ϮϱͿ S ;чϭϲͿ I ;чϰͿ S ;чϭͿ 
ER32 M. morganii S (4) R ;шϯϮͿ R ;шϯϮͿ - R ;шϲϰͿ R ;шϲϰͿ R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ R (8) - R ;шϴͿ S (0.5) R (128) R ;шϭϮϴͿ R (8) 
ER33 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (8) R (16) R (32) R (32) S ;чϬ.ϮϱͿ S ;чϮϬͿ S (чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ R (64) S ;чϭͿ 
ER34 M. morganii I (16) R ;шϯϮͿ R ;шϯϮͿ - R ;шϲϰͿ R (4) R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ R ;шϭϲͿ - R ;шϴͿ S ;чϬ.ϮϱͿ R (128) I ;чϰͿ R ;шϭϲͿ 
ER35 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (2) R (4) R (16) R (16) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S (1) S ;чϬ.ϮϱͿ S ;чϭϲͿ I (8) S ;чϭͿ 
ER36 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (2) R (4) R (32) R (32) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S (1) S ;чϬ.ϮϱͿ S ;чϭϲͿ I (8) S ;чϭͿ 
ER37 E. cloacae S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (2) R (4) R ;шϲϰͿ R ;шϲϰͿ S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭ) S S (0.5) S ;чϬ.ϮϱͿ R (128) I (8) S ;чϭͿ 
ER38 M. morganii S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (4) R (4) R ;шϲϰͿ - R ;шϰͿ S ;чϮϬͿ S ;чϬ.ϱͿ R (8) - R ;шϴͿ S ;чϬ.ϮϱͿ S ;чϮͿ I ;чϰͿ R (8) 
ER39 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (8) R (16) R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S R ;шϴͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ R (64) S ;чϭͿ 
ER40 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - S ;чϭͿ S ;чϭͿ R (16) R (16) R ;шϰͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S R ;шϴͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ R (64) S ;чϭͿ 
ER41 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - S ;чϭͿ S ;чϭͿ R (16) R (16) R ;шϰͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S R ;шϴͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ R ;шϭϮϴͿ S ;чϭͿ 
ER42 E. aerogenes S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (8) R ;шϲϰͿ R ;шϲϰͿ R ;шϲϰͿ S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ I (64) R ;шϭϮϴͿ S ;чϭͿ 
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ER43 E. coli S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (2) R (4) R (32) R (32) S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ S ;чϭϲͿ R ;шϭϮϴͿ S ;чϭͿ 
ER44 E. aerogenes S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (8) R (16) R ;шϲϰͿ R ;шϲϰͿ S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ R (128) R ;шϭϮϴͿ S ;чϭͿ 
ER45 E. aerogenes S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (16) R (16) R ;шϲϰͿ R ;шϲϰͿ S ;чϬ.ϮϱͿ S ;чϮϬͿ S ;чϬ.ϱͿ S ;чϭͿ S S ;чϬ.ϭϮͿ S ;чϬ.ϮϱͿ I (64) R ;шϭϮϴͿ S ;чϭͿ 
ER46 P. stuartii S ;чϮͿ R ;шϯϮͿ R ;шϯϮͿ - R (2) R (16) R ;шϲϰͿ R ;шϲϰͿ R ;шϰͿ R ;шϯϮϬͿ I (1) R (8) - R ;шϴͿ S (1) R (256) I ;чϰͿ R (8) 
 
Antibiotic abbreviations: AMK – amikacin; AMC - amoxicillin-clavulanic acid;  AMP – ampicillin; CEF – cephalothin; CTX – cefotaxime;  CAZ – ceftazidime; CXMa – 
cefuroxime axetil; CXMs –cefuroxime sodium; CIP – ciprofloxacin; SXT – trimethoprim-sulfamethoxazole; ERT – ertapenem; GEN – gentamicin; IPM – imipenem; LVX – 
levofloxacin; MEM – meropenem; NIT – nitrofurantoin; TZP -  piperacillin/tazobactam; TOB – tobramycin 
 
 
    
 
